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CHAPTER I: INTRODUCTION 
 
Inflammatory diseases such as sepsis or type 2 diabetes have more in common 
than some might imagine. First, both diseases represent huge costs in United States 
heath care. In 2008, $14.6 billion was spent for the treatment of sepsis (48), and in 
2012, $245 billion was the estimated total economic cost of diabetes (2). While diabetes 
and acute or chronic inflammation are vastly different in etiology and pathology, both 
settings are associated with an elevation in plasma pro-inflammatory cytokines such as 
interleukin-6 and feature profound alterations in glucose homeostasis. In both cases, 
controlling glycemia can improve patient morbidity and mortality (135). Much of 
glucoregulatory research has focused on either ameliorating the insulin resistance that 
develops in tissues such as liver, muscle, and adipose. However, a story that has been 
less explored until recent years is that of glucagon. In light of recent work, the field is 
beginning to shift  to  a  more  “glucagonocentric”  view  of  managing  glycemia  (136).   
Septic patients often exhibit hyperglucagonemia (85), and in diabetics, the ratio 
of glucagon:insulin or the absolute glucagon concentration in plasma is often elevated. 
Recent work has pointed to a critical role of glucagon in contributing to the 
hyperglycemia observed in rodent models of diabetes. Hyperglycemia associated with 
insulin deficiency does not manifest in the absence of glucagon-dependent signaling 
(73). While this work was done in models of type 1 diabetes rather than type 2 diabetes, 
it should be mentioned that both disease states are associated with elevated plasma 
glucagon and elevated pro-inflammatory cytokines. Therefore, new strategies to limit 
hyperglycemia by reducing glucagon secretion could make vast advancements in 
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maintenance of glucose homeostasis and improve patient morbidity and mortality for 
multiple inflammatory diseases.  
Current therapeutic strategies for the management of glycemia in type 2 diabetes 
are mostly focused on either enhancing insulin secretion or increasing insulin sensitivity. 
Common treatments for managing type 2 diabetes are not typically used for individuals 
with sepsis. Currently, the most common method to manage the hyperglycemia in septic 
individuals is via exogenous insulin administration. However, hypoglycemia is a 
common complication in these patients as clinicians try to regulate glycemia with insulin, 
and incidents of hypoglycemia also increase patient morbidity and mortality. An 
alternative (or perhaps an additional) approach to current therapies in the treatment of 
diabetes or sepsis may be to limit glucagon secretion by reducing inflammation.  
Research from the McGuinness lab and others has demonstrated that the 
inflammatory cytokine, interleukin-6 (IL-6) can regulate the secretion of glucagon from 
alpha cells of the pancreatic islets of Langerhans (6, 34, 133). Moreover, others have 
demonstrated that inhibition of IL-6 signaling improves HbA1c levels in diabetic 
individuals with rheumatoid arthritis (97). While Ellingsgaard and colleagues found that 
IL-6 can regulate glucagon secretion in a slow, transcriptional-dependent manner (34), 
work from the McGuinness lab has demonstrated that IL-6 can also act more rapidly to 
increase plasma glucagon (133). Therefore, the site by which IL-6 acts to enhance 
glucagon secretion is not yet clear. The primary goal of my thesis work was to 
determine the route by which IL-6 enhances glucagon secretion.  
Given that the IL-6 receptor subunit (IL-6Rα)   is   expressed   rather   ubiquitously  
throughout the body, there are several conceivable sites of action for circulating IL-6 to 
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enhance glucagon secretion from alpha cells. First of all, IL-6 could directly act on islet 
alpha cells (in a manner faster than what was previously characterized) (34) (Figure 
1.1). Alternatively, IL-6 could be acting within the brain to modulate autonomic drive to 
the islet. IL-6 can cross the blood-brain barrier (5) as well as be produced within the 
brain (36), and IL-6 receptors are expressed rather ubiquitously throughout the brain, 
including within critical glucose-sensing brain regions (137). Peripheral tissues such as 
the liver are exquisitely sensitive to IL-6. It is possible that IL-6 acts through peripheral 
tissues to either stimulate release of an endocrine factor or modulate vagal afferents, 
which, in turn, modulate autonomic drive to the pancreas.  
 
 
 
Figure 1.1: Ways in which IL-6 may stimulate glucagon secretion. IL-6 may 
either (1) act directly on the alpha cells, (2) act via brain to modulate autonomic 
drive to the pancreas, or act on peripheral tissues to either (3) modulate vagal input 
or (4) promote endocrine factor secretion to modulate glucagon secretion.  
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The body of work in this dissertation focused on discovering whether IL-6 could 
modulate glucagon secretion by 1) directly acting on islets and/or 2) directly acting 
within the brain to modulate autonomic drive. Given that the McGuinness lab observed 
that IL-6 elicited a rapid glucagon secretory response in their studies (133), my 
hypothesis was that IL-6 does not act directly on islets; the interaction of IL-6 with islets 
has previously been characterized to be a slow, transcriptional-dependent process (34). 
Instead, I hypothesized that IL-6 acts in a more rapid manner by modulating autonomic 
drive through direct actions within the brain. I focused on determining the role of central 
IL-6 on glucagon secretion in two known settings normally associated with both 
elevated plasma pro-inflammatory cytokines and elevated plasma glucagon, 1) 
endotoxemia (using lipopolysaccharide) and 2) hypoglycemia (using hyperinsulinemic/ 
hypoglycemic clamps). 
The findings of this work suggest that IL-6 is a central player in glucagon 
secretion in multiple inflammatory settings. IL-6 acts within the brain to augment 
glucagon secretion both following a lipopolysaccharide challenge as well as during 
insulin-induced hypoglycemia. Interestingly, central IL-6 has no effect on glucagon 
secretion alone; rather it only amplifies glucagon secretion in known settings of elevated 
adrenergic tone. In contrast to my initial hypothesis, IL-6 was not only found to act via 
the brain to augment glucagon secretion, but it also modulated glucagon secretion from 
isolated islets. As in the brain, IL-6 alone did not have an effect on glucagon secretion. 
However, IL-6 augmented epinephrine-stimulated glucagon secretion. Given that 
autonomic drive and plasma epinephrine increase following lipopolysaccharide 
challenge as well as during insulin-induced hypoglycemia, these results suggest that IL-
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6 can not only enhance neural drive to the islet in settings of stress, but it can also 
increase the effectiveness of epinephrine at islets to amplify glucagon secretion. 
 
Lipopolysaccharide as a model for glucagon secretion  
 
Characteristics of lipopolysaccharide 
 
There are three stages involved in pathogenesis of infection. First is the release 
of bacterial toxins. In the case of Gram-negative bacterial infection, lipopolysaccharide 
(LPS) is one of those toxins released. The second phase in the pathogenesis of 
infection is the innate immune system’s response. Resident macrophages primarily in 
the liver release cytokines and drive the overall response to the pathogen. Both pro- 
and anti-inflammatory cytokines are normally released in the response, and this 
response helps to mobilize the immune system to attack and destroy the pathogen. 
However, if the cytokine response is too robust (stage 3), and if the pro-inflammatory 
mediators far exceed the anti-inflammatory mediators, sepsis can develop. Sepsis is the 
body’s   response   to   systemic   infection  and   is   defined  as   an   infection accompanied by 
two or more of the following: hypo or hyperthermia, tachycardia, tachypnea, and 
drastically altered leucocyte profiles (leukocytosis or leukopenia) (82). The resultant 
vascular and metabolic responses can ultimately lead to organ system collapse and 
death.  
LPS interacts with the innate immune system via the Toll-like receptor 4 (TLR4) 
to activate macrophages. Toll-like receptors are expressed by select cells of the innate 
immune system (such as macrophages and dendritic cells), and they normally 
recognize specific regions of common pathogens called pathogen-associated molecular 
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patterns (PAMPs). Signaling through TLR4 results in a cascade of events that will 
ultimately drive the destruction of the PAMP-containing (LPS-harboring) invaders 
(bacteria in this case). Demonstrating the importance of TLR4, animals lacking TLR4 
are protected from the negative metabolic and cardiovascular effects of LPS (39, 57). 
Further, various single nucleotide polymorphisms on the TLR4 gene have been 
identified that are associated with increased susceptibility of individuals to Gram-
negative bacterial infection (76, 91, 113).  
Administration of LPS (in the absence of Gram-negative bacteria) can mimic 
many of the cardiovascular and metabolic responses that are observed with exposure to 
Gram-negative bacteria. Thus, LPS has been used as a model system to understand 
the complex interaction between the pathogen, the immune system, and metabolism. In 
response to high doses of LPS, there is systemic vasodilation, cardiac dysfunction and 
a robust activation of the neuroendocrine system. With even higher doses, organ 
dysfunction can manifest (as is observed clinically during severe sepsis). Because the 
dose of LPS can be easily manipulated, investigators can control the extent of the 
magnitude of the activation. Importantly, low doses of LPS (1 mg/kg) were used in the 
studies presented within this dissertation; this dose is associated with neither organ 
dysfunction nor cardiovascular complications and allowed us to focus solely on the 
metabolic response to LPS.  
 
The metabolic response to lipopolysaccharide 
 
In response to bacterial invasion, the host activates an inflammatory response 
that alters both the cardiovascular and metabolic systems. The cardiovascular 
responses include marked vasodilation, impaired cardiac function, a redistribution of 
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organ blood flow, and, depending upon the severity of the insult, either an increase or 
decrease in cardiac output. These cardiovascular alterations are also associated with 
robust metabolic and neuroendocrine responses that interact to have profound effects 
on metabolism, ultimately leading to the acceleration of glucose, fat (increased 
lipolysis), protein (muscle proteolysis), and amino acid flux. The net effect is a loss of 
protein coupled to hyperglycemia (85).  
A net release of glucose from the liver is observed early with a high-dose (10 
mg/kg) challenge of LPS (70). Meinz demonstrated that this early elevation is most 
likely due to increased glycogenolysis rather than gluconeogenesis (88), while others 
showed that increased gluconeogenesis becomes more important with longer exposure 
time (85). Glycemia is briefly elevated despite concurrently elevated plasma insulin (22). 
Work conducted by Clemens and colleagues suggests that the LPS-induced insulin 
resistance occurs both at the liver (sustained hepatic glucose production in spite of 
elevated circulating insulin) as well as the muscle and other peripheral tissues 
(decreased insulin-stimulated glucose utilization) (22). During this time, there is also 
elevated plasma lactate, increased amino acids, and elevated plasma glucagon (25, 
58). It has been previously demonstrated that substrate supply alone does not facilitate 
gluconeogenesis; animals treated with the gluconeogenic precursors alanine or lactate 
do not increase production of glucose (24, 28). However, elevated fatty acids in the 
presence of gluconeogenic precursors promotes gluconeogenesis (86). Acute 
inflammation increases adipose tissue lipolysis and thus increases availability of fatty 
acids (146); thus, this increased gluconeogenic precursor supply combined with the 
elevated supply of fatty acids could explain the increased gluconeogenesis.  
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Depending on the dose of LPS, either hyperglycemia or hypoglycemia can 
develop. High-dose LPS is often used in animal models to mimic some of the 
immunologic complexity of sepsis that is observed clinically. Following exposure to LPS, 
The transient hyperglycemia as described above can be followed by moderate to severe 
hypoglycemia. The hypoglycemia that develops is due to both depleted glycogen stores 
as well as an impairment in gluconeogenesis (69). However, sometimes despite 
impaired liver function, gluconeogenesis can be increased due to the combined effect of 
the profound activation of the neuroendocrine system and the increase in 
gluconeogenic substrate supply (85). Table 1.1 summarizes the metabolic and 
neuroendocrine responses that were found following exposure to high-dose LPS. 
  
Table 1.1: The metabolic and neuroendocrine response to high-dose endotoxin.  
 
 
 
 
As with high dose administration, animals treated with low-dose LPS can display 
transient hyperglycemia. However, treatment with low-dose LPS does not result in the 
profound hypoglycemia that can often be observed with high-dose treatment. Rather, 
Adapted from Lang et al. (1987). Circ Shock. and Buday et al. (1986) Circ Shock. 
Ra indicates endogenous glucose production.  
 
Analyte % Change from Basal 
Glucose, 1 hour 
Glucose, 4 hours 
Lactate, 4 hours 
Insulin, 4 hours 
Glucagon, 4 hours 
Norepinephrine, 4 hours 
Epinephrine, 1 hour 
Epinephrine, 4 hours 
Corticosterone, 4 hours  
 
Ï69% 
Ï19% 
Ï86% 
Ð29% 
Ï340% 
Ï750% 
Ï3300% 
Ï2500% 
Ï300% 
 
Metabolic Parameter % Change from Basal 
Ra, 1 hour 
Ra, 4 hours 
Glucose recycling, 4 hours 
Glucose clearance, 1 hour 
Liver Glycogen, 4 hours 
Muscle Glycogen, 4 hours 
 
Ï70% 
Ï28% 
Ï290% 
Ï17% 
Ð86% 
Ð27% 
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blood glucose levels return to basal levels gradually without exhibiting hypoglycemia. 
Lang and colleagues suggest that hepatic glucose production can be maintained in this 
setting to maintain a constant supply of glucose for peripheral tissue demands (70).  
 
The cytokine response to lipopolysaccharide 
 
Activation of macrophages induces production of both pro- and anti-inflammatory 
cytokines. Pro-inflammatory cytokines released include TNF-alpha, interleukin-1 beta, 
and interleukin-6. TNF-alpha is the earliest cytokine to increase in response to systemic 
infection, and it has been characterized as being one of the most important cytokines in 
terms of its involvement in the pathophysiology of sepsis (82, 109). The pro-
inflammatory cytokines promote leukocyte adhesion on endothelial cells, induce the 
activation of inducible nitric oxide synthase (iNOS) to generate large amounts of the 
vasodilator, nitric oxide, promote coagulation, and promote the release of metabolites of 
arachidonic acid.  
Anti-inflammatory cytokines, on the other hand, work to limit the extent of 
inflammation promoted by the pro-inflammatory cytokines. For instance, anti-
inflammatory cytokines inhibit TNF-alpha, effectively functioning in a negative feedback 
manner to both decrease production of pro-inflammatory mediators and moderate their 
effects. However, it is presumed that in cases such as sepsis, there is an imbalance 
between pro-inflammatory and anti-inflammatory cytokines, and this imbalance leads to 
pathology (109).   
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The neuroendocrine response to lipopolysaccharide 
 
 LPS stimulates activation of multiple facets of the neuroendocrine system. The 
hypothalamic-pituitary-adrenal (HPA) axis is activated by LPS. Ultimately, this increases 
the production and secretion of the glucocorticoid corticosterone, which helps to limit the 
extent of inflammation. Next, LPS activates the autonomic nervous system. In particular, 
the sympathetic branch of the autonomic nervous system is intimately associated with 
the immune system and can function as a modulator of the immune response. Finally, 
LPS regulates production of endocrine hormones such as insulin and glucagon.  
 
The hypothalamic-pituitary-adrenal axis is activated by inflammation 
 
A rise in pro-inflammatory cytokines in the plasma (as may occur during an 
inflammatory event) can activate the HPA axis. Stimulation of the HPA axis results in 
hypothalamic production of corticotropic releasing hormone (CRH), entry into the portal 
vasculature, and subsequent activation of corticotroph cells in the anterior pituitary. The 
corticotroph cells then release adrenocorticotropic hormone (ACTH) into the 
bloodstream, which stimulates cortical cells of the adrenal gland to synthesize and 
secrete glucocorticoids (such as cortisol in the human and corticosterone in the mouse) 
(122). Glucocorticoids limit the inflammatory event by reducing levels of pro-
inflammatory cytokines (IL-1-beta, IL-6, TNF-alpha) and increasing the levels of anti-
inflammatory cytokines (IL-10). Glucocorticoids also negatively feed back at both the 
hypothalamus and pituitary to limit HPA axis activation. The importance of 
glucocorticoid production by adrenocortical cells is illustrated by the fact that rodents 
with adrenalectomy have a higher mortality rate compared to sham operated controls 
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when injected with LPS; further, administration of physiologic levels of glucocorticoid 
reduced mortality following LPS administration (63).  
Importantly, infusion of cortisol in the presence of other stress hormones such 
as glucagon, epinephrine, and norepinephrine, can lead to sustained hyperglycemia 
(10, 44) due to increased gluconeogenesis (87). Removing cortisol from the stress 
hormone infusion (i.e. infusing only glucagon, epinephrine, and norepinephrine) resulted 
in depleted gluconeogenesis, and this was due to a decreased substrate supply (42). In 
these studies, removing cortisol from the infusion mixture also led to reduced hepatic 
glycogen stores; consistent with this, infusion of cortisol alone increases hepatic 
glycogen content (46).   
 
The autonomic nervous system is activated by inflammation 
 
The autonomic nervous system (ANS) can also regulate immune system 
function. The sympathetic nervous system extends pre-ganglionic fibers to the spinal 
cord, and post-ganglionic fibers directly innervate peripheral tissues. In contrast, 
parasympathetic pre-ganglionic fibers extend directly to organs or tissues, and post-
ganglionic fibers extend rather locally. For both the parasympathetic and sympathetic 
neurons, acetylcholine secreted by pre-ganglionic neurons acts on nicotinic 
acetylcholine receptors of post-ganglionic neurons. Sympathetic post-ganglionic 
neurons secrete norepinephrine, which can effect changes in peripheral tissues through 
actions on adrenergic receptors. In contrast, post-ganglionic neurons of 
parasympathetic neurons secrete acetylcholine, which acts via muscarinic acetylcholine 
receptors present on target tissues. The pancreas receives sympathetic fibers from the 
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splanchnic nerve and parasympathetic fibers from the vagus nerve, and at least the 
vagal fibers appear to enter the pancreas through blood vessel walls (9).  
The sympathetic nervous system in particular communicates with the immune 
system. Immune system organs such as the spleen, thymus, and lymph nodes are 
highly innervated by sympathetic fibers. Further, lymphocytes express adrenergic 
receptors, and activation of these immune cells by either norepinephrine or epinephrine 
can alter production of both pro- and anti-inflammatory cytokines. Different populations 
of immune cells are differentially affected by adrenergic signaling. In some cases, 
norepinephrine and epinephrine decrease the production of pro-inflammatory cytokines 
and increase the production of anti-inflammatory cytokines, although this is not always 
the case (37). In effect, the autonomic nervous system can work with the glucocorticoids 
of the HPA axis to modulate the inflammatory environment during inflammation.  
Besides its effect on immune function, activation of the sympathetic nervous 
system has been demonstrated to be important in the early glucose response to 
infection. In particular, hepatic glucose production is stimulated by high-dose endotoxin, 
and this is prevented with combined alpha- and beta-adrenergic blockade (49). The 
findings of this work suggest that the increased hepatic glucose production is not due to 
a change in plasma glucagon. However, others have demonstrated that adrenergic 
stimulation can modulate glucagon secretion from the alpha cell (45, 67). Data 
presented in this dissertation also points to a role of adrenergic signaling in promoting 
the glucagon response to LPS.  
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Secretion from the endocrine pancreas is modulated by inflammation 
 
The pancreatic islets of Langerhans make up about 1-2% of the entire pancreas 
and represent the endocrine portion of the pancreas. Within islets are specific cell 
subtypes, including glucagon-secreting alpha cells, insulin-secreting beta cells, 
somatostatin-secreting delta cells, and pancreatic polypeptide-secreting epsilon cells. In 
mouse, the alpha cells surround a core of primarily beta cells (with few delta, gamma, 
and epsilon cells scattered within the beta cell core). In humans, the islet cell subtypes 
are more scattered, and alpha cells can make up upwards of 50% of the islet, 
demonstrating a potentially more important role of alpha cells in humans.  
 
The pancreatic beta cell 
 
The endocrine pancreas is exquisitely responsive to changes in metabolism and 
the inflammatory state. Most explored within the islet has been the regulation of the 
insulin-secreting beta cell. The primary mechanism by which the beta cell is modulated 
is glucose. When glucose concentrations rise (as might occur following a meal), 
increased glucose metabolism within the beta cell results in an increase in the ratio of 
ATP:ADP. This triggers a closing of potassium-sensitive ATP channels (KATP-channels), 
which then depolarizes the plasma membrane to activate voltage-dependent calcium 
channels. Calcium influx then triggers insulin secretion by the exocytosis of insulin 
granules (93). This mechanism is thought to dominate the first-phase insulin response, 
while other mediators may facilitate sustained second-phase insulin secretion (53, 92).  
Still, other channels have recently been identified to play a role in glucose-mediated 
insulin secretion, including the two-pore-domain acid-sensitive potassium channel 
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(TASK-1) (27), indicating that the original picture for glucose-stimulated insulin secretion 
is more complex than previously imagined. 
Beta cells are also regulated by a number of neuroendocrine factors, including by 
the incretin factor, glucagon-like peptide-1 (GLP-1). GLP-1 increases the activity of 
adenylate cyclase, which increases intracellular cyclic adenosine monophosphate 
(cAMP). It is possible that one of the ways by which GLP-1 stimulates insulin secretion 
is through increased cAMP, which has been suggested to modulate insulin in both 
protein kinase A (PKA)-dependent and independent mechanisms (32, 115). One of the 
calcium channels inhibited by GLP-1 in beta-cells is the voltage-dependent potassium 
channel (Kv). Stimulation of Kv channels results in repolarization of the plasma 
membrane, which inhibits calcium influx. Thus, GLP-1 promotes insulin secretion by 
inhibiting activation of Kv channels (80, 115).  
The autonomic nervous system can also modulate secretion of insulin from beta-
cells. The parasympathetic nervous system stimulates insulin secretion. Vagotomized 
(i.e. lacking parasympathetic input) rodents exhibit a diminished insulin response to a 
glucose challenge (125). As mentioned above, parasympathetic post-ganglionic fibers 
transmit acetylcholine into the synapse. Mouse pancreatic islets have been 
demonstrated to stain densely positive at the core (mainly beta cells) for vesicular 
acetylcholine transporter (vAChT), which is a marker for cholinergic neurons and axons. 
Interestingly, however, human islets expressed sparse amounts of vAChT, suggesting a 
potentially different involvement of the parasympathetic nervous system on islets (107). 
In contrast, the sympathetic nervous system can actually inhibit or stimulate insulin 
secretion; alpha-2 adrenergic agonists inhibit glucose-stimulated insulin secretion in 
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vivo (102), while beta-2 adrenergic agonists stimulate insulin secretion (1). In vivo, the 
net effect of sympathetic stimulation is inhibitory (74, 105).  
During inflammation, insulin levels are elevated, even in the presence of 
hyperglycemia and elevated norepinephrine spillover from nerve termini as well as 
circulating epinephrine (85). One of the proposed mediators of the insulin secretion is 
GLP-1. Recent work from Nguyen et al. demonstrated that with low-dose LPS (2 
mg/kg), the increase in plasma insulin correlates with GLP-1 (0.709). Further, wild-type 
mice administered the dipeptidyl peptidase-4 (DPP4) inhibitor, sitagliptin (effectively 
preventing the breakdown of plasma GLP-1) exhibited a decreased glucose excursion 
following an oral glucose tolerance test. Conversely, treatment with the GLP-1 receptor 
antagonist exendin-9 increased the glucose excursion, suggesting that signaling 
through GLP-1 may increase insulin secretion in settings of inflammation. It should be 
noted, however, that plasma insulin levels were not assessed in the glucose tolerance 
tests (94). GLP-1 also can act via other tissues (such as brain) in addition to the beta 
cell to modulate glucose tolerance (16). Others have also demonstrated that either low-
dose LPS (0.1 mg/kg) or administration of individual pro-inflammatory cytokines such as 
TNF-alpha, IL-1 beta, and IL-6 increases plasma GLP-1. Interestingly, they found that 
IL-6 is both sufficient and necessary for the increase in plasma GLP-1 following LPS 
exposure (61). Work from Ellingsgaard and colleagues suggests that GLP-1, which is 
normally produced in L cells of the intestine, may also be produced directly within islets 
to act as a paracrine factor (35). 
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The pancreatic alpha cell 
 
Like beta cells, Alpha cells are a highly regulated (if not perhaps even more 
regulated) cell population. The mechanism for glucose-dependent glucagon secretion is 
slightly more complicated than in the beta cell. While alpha cells also have KATP-
channels, the closing of these channels (as would happen with a high ATP:ADP ratio 
and high glucose), inhibits glucagon secretion. Why does closing KATP-channels 
facilitate insulin secretion in one cell population and inhibit glucagon secretion in 
another? The reason lies in the presence of additional ion channels present in the alpha 
cell (Figure 1.2). In high-glucose conditions, blocking KATP-channels depolarizes the 
membrane potential beyond a range where voltage-dependent channels can trigger 
calcium influx (79). In contrast, in low glucose, KATP-channels are moderately active, 
allowing the membrane potential of the alpha cell to open voltage-dependent L- and N-
type calcium channels as well as voltage-dependent sodium channels. The net result is 
an action potential, which triggers the influx of calcium and glucagon granule exocytosis 
(59, 103).   
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The complex regulation of the alpha cell extends far beyond glucose. Regulation 
of alpha cells can be divided into three categories: intra-islet regulation, 
hormonal/nutrient regulation, and neural regulation. These forms of regulation may even 
occur (and likely do occur) simultaneously, meaning that the alpha cell must integrate 
the regulatory signals to determine whether to enhance or suppress glucagon 
production and/or secretion.  
Within the islet, several factors can influence glucagon secretion. First, insulin 
can inhibit glucagon secretion. Kawamori et al. demonstrated that alpha-cell-specific 
knock-out of the insulin receptor resulted in glucose intolerance and mild hyperglycemia 
accompanied by hyperglucagonemia in the fed state (64). Glucagon secretion is also 
inhibited by somatostatin (124). Cabrera et al. found that glutamate, which is co-
Figure 1.2: Schematic of glucose-regulated glucagon secretion from the 
alpha cell. (Figure from Jacobson et al. (2009). Diabetes.) Shown are conditions in 
which depolarization and calcium influx is permissive (low glucose; left panel) and 
conditions in which depolarization and calcium influx do not occur (high glucose; 
right   panel).   The   figure   in   orange   marked   “unknown”   represents   a   glucose-
dependent pathway that facilitates repolarization of the plasma membrane. The 
islet factors depicted regulate the alpha cell independently of glucose. SST, 
somatostatin.  
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secreted within glucagon-containing secretory granules, can act in a positive feedback 
manner to promote glucagon secretion in low glucose conditions (17). Co-secreted from 
insulin granules is zinc, which Gyulkhandanyan et al. suggested may have a modulatory 
effect on glucagon secretion (47). Additionally, glucagon itself can enhance glucagon 
secretion (77). 
In terms of circulating factors that modulate glucagon secretion, amino acids 
such as L-arginine are also potent stimulators of glucagon secretion. Circulating fatty 
acids such as palmitate have also been found to stimulate glucagon secretion. In 
response to food intake, the incretin hormone GLP-1 (discussed above) is secreted 
from intestinal L-cells, and it acts to promote insulin secretion and suppress glucagon 
secretion. Another incretin, glucose-dependent insulinotropic polypeptide (GIP), 
stimulates both glucagon and insulin secretion (103).  
As mentioned previously, islets are innervated by both parasympathetic and 
sympathetic fibers (107), and both branches of the autonomic nervous system can 
stimulate glucagon secretion (i.e. adrenergic and cholinergic signaling). γ-Amino-butyric 
acid (GABA) is synthesized from glutamate and acts as an inhibitory neurotransmitter in 
the central nervous system. Islets receive neural input from GABAergic neurons (120), 
and thus it is possible that this neurotransmitter may act to inhibit alpha cell function. 
Interestingly, the GABA-A receptor is recruited to the plasma membrane via an insulin-
dependent pathway (147), suggesting collaborative negative feedback on the alpha cell 
in settings where insulin is secreted and glucagon secretion is suppressed. 
 In the presence of inflammation, hyperglucagonemia is often observed in spite of 
the elevation of several factors known to inhibit glucagon secretion: hyperglycemia, 
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hyperinsulinemia, and elevated GLP-1. With high adrenergic drive from the sympathetic 
nervous system, perhaps elevated circulating catecholamines, inflammatory mediators, 
and elevated fatty acids drive glucagon secretion in this setting. Work presented within 
this dissertation suggests that the central nervous system is required for the glucagon 
response to LPS; in the absence of neural input (achieved through ganglionic 
blockade), the glucagon response to LPS is completely abrogated. I also found that the 
pro-inflammatory cytokine, interleukin-6 (IL-6) augments glucagon secretion following 
LPS by acting within the brain to augment autonomic drive and increase the 
effectiveness of epinephrine directly at the islet.  
 Clearly, the regulation of the alpha cell is complex and appears to be dependent 
on the milieu of factors present at the islet at any given time. Ultimately, alpha cells 
integrate endocrine, paracrine, and neural input. How the integration occurs may be 
context-dependent, making the study of the alpha cell rather complicated.  
 
The periphery signals to the brain during inflammation  
 
In addition to signaling from the brain outward to modulate the inflammatory 
response, it is also important to consider signaling from the periphery to the brain in 
cases of inflammation. How do cytokines produced in the periphery signal to the brain? 
There are multiple ways in which communication may occur. One manner is via 
entrance directly into   the   brain   through   “leaky”   regions   where   the   blood-brain-barrier 
(BBB) is less intact. Alternatively, the cytokines may be directly taken up into the brain, 
as has been demonstrated with the cytokine, IL-6 (5). Still, other possibilities include 
indirect communication via the vagus or via second messengers such as nitric oxide or 
prostaglandins (37). Researchers have demonstrated that communication of peripheral 
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inflammation to the brain is necessary for a full inflammatory event to occur. For 
example, mice that undergo vagotomy have reduced the expression of pro-inflammatory 
cytokine mRNA in the brain following an LPS injection. Furthermore, the effect of LPS 
(in this case, sleep) was lost with vagotomy (150). 
 
In sum, inflammation results in profound metabolic, neuroendocrine, and 
immunologic changes. Preventing hyperglycemia in this setting can improve patient 
morbidity and mortality. Controlling hyperglucagonemia may represent a viable 
therapeutic option for management of glycemia. However, the response to systemic 
inflammation is complex, and there is still much to be learned regarding the regulation of 
the alpha cell in settings of inflammation. 
 
Inflammation is not the only system that relies on glucagon secretion for normal 
function 
 
Other settings beyond that of infection or endotoxemia are associated with 
elevated glucagon secretion. Two well-characterized settings include exercise and 
hypoglycemia. Further, in type 2 diabetes, patients often present with 
hyperglucagonemia. Interestingly, not only are all three of these settings associated with 
elevated plasma glucagon, but they are also associated with elevated plasma pro-
inflammatory cytokines, specifically interleukin-6 (7, 30, 100).  
Wasserman et al. demonstrated that glucagon regulates upwards of 65% of the 
increase in hepatic glucose production observed during exercise. Glucagon contributes 
to both elevated glycogenolysis and gluconeogenesis in this setting (144). Further, in 
healthy human subjects, Lavoie and colleagues demonstrated that suppression of 
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glucagon ablated the rise in hepatic glucose production (71). Exercise, like acute 
inflammation, is a setting associated with elevated autonomic drive and increased 
plasma interleukin-6 (100). While plasma norepinephrine and epinephrine increase 
during exercise, the relevance of direct neural input to the pancreas during exercise 
remains controversial (23).  
As in exercise and acute inflammation, glucagon is a key player in the response 
to hypoglycemia. Further, while the factors controlling the glucagon response to 
inflammation have not been extensively examined, they have been carefully studied 
with regard to the response to hypoglycemia. Besides glucose-regulated glucagon 
secretion (discussed above), a critical factor in driving glucagon secretion is central 
autonomic drive to the pancreas.  
 
Hypoglycemia as a model for glucagon secretion 
During hypoglycemia, the body must respond quickly to plummeting glycemia to 
ensure that the brain continues to receive the required amount of glucose to maintain 
normal processes. Glucose-sensing neurons within critical brain regions (mostly within 
the hypothalamus; see below) detect plummeting glycemia and respond ultimately by 
increasing autonomic drive, stimulating glucagon secretion from the islet and 
epinephrine secretion from the adrenal gland. Sites of glucoregulation as well as 
examples of central modulation of this so-called “counter-regulatory response” are 
shown below. A focus has been placed on a well-characterized glucoregulatory region, 
the ventromedial hypothalamus, as it appears to have a critical role in the glucagon 
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secretory response to hypoglycemia. Incidentally, this region also expresses receptors 
for interleukin-6 (138).  
 
Sites of glucoregulation within the nervous system 
 
There are three steps involved in the neural control of blood glucose: first, 
glucose levels must be detected. Next, information regarding the state of blood glucose 
must be integrated within the brain. Finally, the brain must effect an autonomic 
response to the change in blood glucose. 
Glucose-sensitive neurons are found throughout the body, including in the 
mouth, gut, portal vein, carotid body, and in specific regions of the brain (discussed 
below). There are two types of glucose responsive neurons: glucose-excited and 
glucose-inhibited. As the names suggest, these neurons either increase or decrease 
their firing when blood glucose increases. When blood glucose drops, the system 
reverses; glucose-excited neurons cease firing, and glucose-inhibited neurons increase 
firing. One can imagine how this glucose-sensing system could facilitate careful 
modulation of glucose homeostasis. 
In general, the anatomical regions of the brain that are involved in glucose 
sensing and regulation exist in the hindbrain and in the hypothalamus. However, as 
mentioned above, glucose-sensitive neurons are also found outside of the central 
nervous system. For instance, the vagal afferents that project from the portal/mesenteric 
vein to the hindbrain and the hypothalamus are part of the neural reflex that controls 
first-phase insulin secretion from the pancreas. Regions of the brain containing glucose-
sensing neurons include the lateral hypothalamic area (LHA), the dorsomedial 
nucleus (DMN) of the hypothalamus, the ventromedial hypothalamus (VMH), the 
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arcuate nucleus (ARC), and the hindbrain. These regions are shown in orange below in 
Figure 1.3. 
 
 
 
 
The ventromedial hypothalamus: a well-characterized site of glucagon regulation 
 
Starting   from   the   beginning   of   the   1970’s,   research   has   pointed   out   that   the  
ventromedial nucleus of the hypothalamus (VMH) is an important glucoregulatory site. 
Frohman and Bernardis showed in 1971 using electrical stimulation of the VMH that 
hyperglycemia occurs almost immediately during a 3 minute stimulation (41). This effect 
did not occur when stimulation was applied to the cerebral cortex or the lateral 
hypothalamus. Increases in plasma growth hormone also occurred following stimulation, 
although the response was delayed 2-5 minutes compared to the rise in plasma 
glucose. Frohman and Bernardis hypothesized that two responses may result from the 
same neurons. Further, adrenalectomy did not ablate the hyperglycemic response to 
Figure 1.3: The neural network for glucose-sensing. The ventromedial 
hypothalamus (VMH) extends projections to the dorsomedial nucleus (DMN), the 
lateral hypothalamic area (LHA), the arcuate nucleus (ARC), and to the 
paraventricular nucleus (PVH), an area that integrates glucose sensing. Information 
is integrated in the hypothalamus and hindbrain, which then provides input to motor 
neurons that send input to both the pancreas and adrenal gland. Glucose-sensing 
regions are highlighted in orange. Modified from Beall et al., 2011, AJP.  
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electrical stimulation of the VMH, suggesting that the rise in plasma glucose was not 
epinephrine-mediated.  However, removal of the adrenal did shorten the duration of 
hyperglycemia.  Insulin secretion was suppressed following VMH electrical stimulation. 
However, the suppression was lost following adrenalectomy, suggesting a major role for 
epinephrine and not direct sympathetic stimulation at islets in insulin suppression. 
 In further support of a positive role of the VMH in glucoregulation, the Schulman 
lab demonstrated in Sprague Dawley rats that ablation of neurons in this region using 
ibotenic acid blunted the glucagon as well as the epinephrine and norepinephrine 
response during insulin-induced hypoglycemia (using a hyperinsulinemic/hypoglycemic 
clamp)(13). These results were observed in both mild hypoglycemia (3.0 mM glucose) 
and severe hypoglycemia (2.5 mM glucose).  This effect was not demonstrated when 
ibotenic acid was applied to the frontal lobe, the lateral hypothalamus, or in sham-
operated rats. Taken together with early work by Frohman and Bernardis, it was 
possible that the rise in plasma glucose following electrical stimulation was due to early 
rises in plasma glucagon, epinephrine, and norepinephrine.  
 Borg and colleagues later demonstrated that application of 2-deoxyglucose to the 
region produced a counter-regulatory (glucagon, epinephrine) response in the absence 
of peripheral glucopenia (14). This study was nicely complemented by another study 
from the same laboratory in which peripheral hypoglycemia (hyperinsulinemic/ 
hypoglycemic clamp) was achieved, and glucose was introduced to the VMH (12). By 
administering glucose at the VMH, the counter-regulatory hormone response was 
prevented. This occurred in a dose-dependent manner (more suppression at 100 mM 
vs. 15 mM or 0 mM glucose).  Further, the glucose infusion rate increased upon glucose 
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delivery to the VMH, which is consistent with a failure to secrete counter-regulatory 
hormones.     
Later studies by Beverly et al. demonstrated using microdialysis during insulin-
induced hypoglycemia  (hyperinsulinemic/hypoglycemic clamp) that norepinephrine is 
elevated in both the VMH as well as the periventricular nucleus of the hypothalamus 
(11). GABA concentrations also increased in the VMH in a similar manner to 
norepinephrine release.  The norepinephrine release occurred bimodally—during the 
first 10 minutes and 20-30 minutes following insulin administration. Extracellular 
norepinephrine concentrations in the lateral hypothalamic area were slightly lower, and 
GABA levels remained at baseline. The increases in norepinephrine and GABA in the 
VMH were absent during euglycemic clamp; however, norepinephrine in the 
periventricular nucleus of the hypothalamus still increased, reflecting a direct response 
to hyperinsulinemia.  
Ritter and colleagues demonstrated possible projections to paraventricular 
nucleus of the hypothalamus were responsible for the epinephrine response to insulin-
induced hypoglycemia (104). Ritter injected saporin into the paraventricular nucleus of 
rats. This drug selectively lesions brain epinephrine and norepinephrine-expressing 
neurons in a retrograde manner, meaning the catecholaminergic projecting neurons to 
the hypothalamus were lesioned. These neurons were responsive to insulin-induced 
hypoglycemia, and lesioning reduced the epinephrine response. Glucagon was not 
assessed in these studies (104). 
More recent work from the Sherwin lab has demonstrated a role of adrenergic 
signaling in the counter-regulatory response to insulin-induced hypoglycemia. As 
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previously mentioned, Beverley et al. demonstrated a rise in norepinephrine in the VMH 
during insulin-induced hypoglycemia (11). Szepietowska and colleagues examined the 
role of activating various adrenergic receptors known to be present in the VMH (127). 
Specifically, it was demonstrated that activation of the beta-2 adrenergic receptor via 
VMH bilateral injection of the agonist formoterol increased the counter-regulatory 
(glucagon and epinephrine) response to insulin-induced hypoglycemia. Further, 
antagonism of the beta-2 adrenergic receptor using the compound ICI-118,551 reduced 
the glucagon and epinephrine responses. These findings were paralleled by changes in 
the glucose infusion rate (GIR); agonism of the beta-2 adrenergic receptor decreased 
the GIR, while antagonism increased the GIR. These are consistent with improved and 
reduced counter-regulatory responses, respectively.  
The above findings demonstrate the important role of the VMH in glucagon 
secretion during insulin-induced hypoglycemia in Sprague-Dawley rats. Not only does 
this site play a critical role in glucagon and epinephrine production, but it is also 
regulated locally by catecholamines. Activation of adrenoceptors, particularly the beta-2 
adrenergic receptor, appears to play a role in how great the counter-regulatory 
response can be during an episode of hypoglycemia. Whether or not this region is also 
important in facilitating the glucagon response to other stimuli such as systemic 
inflammation remains an unanswered question. 
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Interleukin-6: A role in glucagon secretion 
 
Interleukin-6: A cytokine with many metabolic roles 
 
Interleukin-6 (IL-6) is a cytokine affecting a wide range of physiological functions, 
including those listed above. First characterized by two independent groups as B-Cell 
Stimulatory Factor (BSF) or T-Cell Replacing Factor (TRF), IL-6 was initially found to 
influence immune system function (62). Since its discovery and eventual isolation, this 
cytokine has been found to elicit a vast number of effects across several organs in 
addition to the immune system. Below are a few established examples of the range of 
IL-6-mediated effects. 
 
Table 1.2: The many roles of IL-6 in physiology 
 
 
IL-6 is a cytokine with a variety of physiologic roles (Table 1.2). IL-6 stimulates 
glucose production from liver and inhibits insulin action on glycogen synthesis (114). In 
muscle, IL-6 stimulates fat oxidation and glucose uptake. Further, IL-6 acts in adipose 
tissue to stimulate lipolysis and inhibit insulin action on glucose transport and 
 
Response to IL-6 Organ/Tissue/Cell Type 
ÏGlucose output, Ðinsulin action on glycogen synthesis 
 
ÏGlucose uptake, fat oxidation, insulin action on glucose transport 
 
ÏLipolysis, Ðinsulin action on glucose transport and lipogenesis 
 
ÏFever, cachexia 
 
ÏInsulin and glucagon secretion 
 
ÏAntibody expression and cytotoxic activity 
 
Liver 
 
Muscle 
 
Adipose Tissue 
 
Brain 
 
Pancreas 
 
Immune: B &   
  Tcyt cells 
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lipogenesis. IL-6 has also been well established as both a pyrogen (via HPA axis 
activation) and a stimulator of the acute-phase protein response via the liver. Plasma IL-
6 is elevated in physiologic and pathophysiologic settings where glucagon is also 
elevated: exercise (100), diabetes (7), and inflammatory stress (55). Furthermore, IL-6 
has become implicated in metabolic disease as a predictive factor in the development of 
type 2 diabetes (121).  
Prior work from the McGuinness lab demonstrated that IL-6 deficient (IL-6 knock-
out) mice have a blunted glucagon response to acute inflammation (lipopolysaccharide, 
LPS) compared to their wild-type littermates. The glucagon response is completely 
rescued by intravenous replacement of IL-6 (133). In those studies, other pro-
inflammatory cytokines (e.g. TNF-alpha and IL-1 beta) increased normally following LPS 
administration, suggesting a specific role for IL-6 in modulating the acute effect of LPS 
on glucagon secretion. IL-6 may also have longer-acting  effects  on  α-cells; human islets 
incubated for 4 or 24 hours in the presence of IL-6 exhibited increased glucagon 
secretion and proglucagon expression compared to untreated controls (34). In contrast, 
the glucagon response that was observed in studies performed by the McGuinness lab 
was much more rapid. Therefore, IL-6 may modulate glucagon secretion in two different 
manners; a slower, transcriptional manner at the islet and a more rapid, yet 
uncharacterized manner. The primary goal of this dissertation was to define the site 
from which IL-6 acts to facilitate this rapid glucagon secretion.  
 
Interleukin-6 signaling 
 
IL-6 signals through the IL-6 receptor (IL-6R). Studies performed from Toshio 
Hirano’s   laboratory   in   the   late   1980s   demonstrated   that   the   IL-6R consists of two 
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subunits. The first subunit, IL-6Rα  (also  known  as  gp80  or  CD126),  is  necessary  for  IL-6 
binding (148). Upon binding of IL-6 to IL-6Rα,   the  second  subunit,  gp130,   is   recruited  
(with stoichiometry 1 IL-6Rα:   2   gp130)   (54, 129). The long cytoplasmic tail of gp130 
functions in signal transduction (54) and is utilized by a number of other interacting 
receptor subunits (termed the IL-6 or gp130 family of cytokine receptors) (62). The 
expression of these two subunits differs across cells. While IL-6Rα  expression  is  more  
restricted, gp130 is more ubiquitously expressed (110). In fact, nine other IL-6 family 
member cytokines have been identified and all use gp130 as a receptor and signal 
transducer, including oncostatin M, LIF, CNTF, CT-1, IL-11, and IL-27 (55).   
IL-6 is thought to signal primarily through two different signaling pathways. First, 
the JAK2/STAT3 pathway is regulated via the YxxQ motif on gp130. The second 
signaling pathway IL-6 employs is the SHP2/Gab/Ras/Erk/MAPK pathway, and this is 
regulated by the cytoplasmic Y759 residue of gp130 (90).  
 
 
 
Figure 1.4: Schematic of Interleukin-6 signaling. IL-6 signals through two 
major signal transduction pathways, JAK2/STAT3 and SHP2/Gab/MAPK 
signaling. (Figure from Hirano (2010), Proc Jpn Acad Ser B Phys Biol Sci.) 
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While IL-6Rα   is  mostly   found  as  an   intramembrane  subunit,   two  known  soluble  
forms (sIL-6Rα)  have  been   identified.  The   first   form   results   from  proteolytic   cleavage,  
while the second results from alternative splicing of its mRNA. When cells do not 
express membrane-bound IL-6Rα,   sIL-6Rα   can   act   agonistically   with   gp130   to  
transduce signals (called the receptor conversion model; (56)). This opens up the 
possibility for IL-6 to act across multiple areas of the body, even when the cells do not 
(at least initially) express IL-6Rα.   
 
Sites of IL-6 production 
 
While several of the innumerable sites of IL-6 action have been defined above, it 
must be stated that IL-6 is produced by a vast assortment of tissues under a wide array 
of physiologic or pathophysiologic settings. Although IL-6 mRNA expression has been 
found in the brain to be increased during inflammation (150), the main site of plasma IL-
6 production is thought to be macrophages (109). In contrast, in type 2 diabetes, which 
is often coupled to obesity, the source of circulating IL-6 is adipose tissue (38). In 
exercise, myocytes secrete IL-6 proportionally to the duration and intensity of the 
exercise (40). The fact that IL-6 is synthesized by different tissues depending on the 
setting points to the important modulatory role of this cytokine.  
 
Clinical significance of IL-6 inhibition 
 
As previously mentioned, IL-6 has become implicated in a wide variety of 
physiological functions. As one might expect, the cytokine has also been demonstrated 
to have a role in pathophysiology. Patients with rheumatoid arthritis (RA) have elevated 
levels of plasma IL-6 (126). One common co-treatment for patients with RA is the drug, 
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tocilizumab (brand name Actemra). This drug is a humanized monoclonal antibody 
against both the soluble and membrane-bound IL-6R. RA patients that also were 
diabetic were treated with tocilizumab, HbA1c levels were improved in this population of 
subjects (97). Investigators did not measure glucagon levels in this population, but one 
possible explanation is that IL-6 signaling inhibition reduced glucagon levels in this 
population, which assisted in the reduction of HbA1c.  
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Specific Aims and Hypothesis 
 
The overall goal for the body of this work was to determine the site(s) of action by 
which interleukin-6 (IL-6) works to augment glucagon secretion. Previous work 
generated from the McGuinness lab demonstrated that IL-6 rescues the glucagon 
secretory response to the endotoxin, lipopolysaccharide (LPS) in IL-6 knock-out mice 
(133). Pro-inflammatory cytokines such as TNF-alpha and IL-1 beta rose similarly to IL-
6 knock-out controls in the absence of a peripheral infusion of IL-6, suggesting that IL-6 
specifically enhances glucagon secretion in settings of inflammation. Other research 
groups have demonstrated that incubation of isolated islets with IL-6 enhances 
proglucagon gene expression as well as glucagon secretion after 4 and 24 hour 
incubations (34). These data suggest that IL-6 has a slow effect on glucagon secretion 
by its direct actions on islets. Therefore, we hypothesized that IL-6 may enhance the 
more rapid glucagon response to LPS by an alternative manner. Knowing that IL-6 can 
cross the blood-brain barrier (5) as well as be produced within the brain (36), and that 
IL-6 receptors are expressed rather ubiquitously throughout the brain (137), we 
hypothesized that the rapid glucagon secretory response to LPS was due to direct 
actions within the brain, which in turn augmented autonomic drive to the islet. To assess 
the action of IL-6 on glucagon secretion via the brain and pancreas, the following 
Specific Aims were designed: 
 
Specific Aim 1: To determine whether central IL-6 alone can augment glucagon 
secretion 
 
Specific Aim 1a: Previous studies did not determine whether IL-6 alone had an 
effect on glucagon secretion in IL-6 knock-out mice. Therefore, it was unclear whether 
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IL-6 alone (in the absence of inflammation) can stimulate glucagon secretion or whether 
IL-6 sustains glucagon secretion only in the presence of an inflammatory stressor. 
Given that our overarching hypothesis is that IL-6 enhances glucagon secretion via the 
brain, Specific Aim 1a sought to determine whether central IL-6 alone could enhance 
glucagon secretion in the absence of an inflammatory stressor.  
Specific Aim 1b: The second objective of this aim was to determine whether 
administration of central IL-6 alone was able to elevate glucagon secretion in the 
presence of LPS.  
Specific Aim 1c: The third objective of this aim was to determine whether central 
IL-6 could augment glucagon secretion during an alternative physiologic stress, 
hypoglycemia.  
 
For all sub aims of Specific Aim 1, it was critical that endogenous IL-6 not be 
produced; this could confound data interpretation. Therefore, mice lacking IL-6 (IL-6 
knock-out mice) were utilized in Specific Aim 1. The results of these studies, therefore, 
would suggest that in the absence of a peripheral rise in IL-6 (i.e. IL-6 is only introduced 
to the brain and not the periphery), central IL-6 alone is sufficient to stimulate glucagon 
secretion, presumably by augmenting autonomic tone to the pancreas or perhaps to the 
adrenal gland. 
 
Specific Aim 2: To determine the role of the autonomic nervous system in the response 
to lipopolysaccharide 
 
 Specific Aim 1 determined that central IL-6 does, in fact, modulate glucagon 
secretion, but only in the presence of a stressor such as LPS or hypoglycemia. The role 
of the autonomic nervous system (ANS) has been examined in depth during insulin-
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induced hypoglycemia.   However,   the   ANS’s   role   in   the   glucagon response to 
inflammation (LPS) had not yet been assessed. Importantly, if one branch of the ANS 
predominated in mediating the glucagon response to LPS, this may provide further 
insight as to how central IL-6 could be interacting to enhance glucagon secretion in 
states of stress.  
 Specific Aim 2a: The objective of this sub aim was to determine whether the 
sympathetic or parasympathetic nervous system predominated in the glucagon 
response to LPS. Pharmacologic blockade of the sympathetic (combined adrenergic 
receptor blockade) or parasympathetic (muscarinic cholinergic receptor blockade) 
nervous system was employed, and the glucagon response to LPS was assessed.  
 Specific Aim 2b: Given that results from Specific Aim 2a suggested that both 
sympathetic and parasympathetic input has an effect on LPS-stimulated glucagon 
secretion, Specific Aim 2b sought to determine whether combined blockade of both the 
sympathetic and parasympathetic nervous system (ganglionic blockade) would have a 
synergistic effect on reducing the glucagon response to LPS.   
Both sub aims of Specific Aim 2 were conducted in wild-type mice.  
Specific Aim 3: To determine whether IL-6 can modulate a rapid glucagon response 
directly on islets 
  
Although we found that central IL-6 alone was sufficient to augment glucagon 
secretion during settings of stress, this did not rule out the possibility that IL-6 could also 
acutely modulate glucagon directly from islets. Therefore, the objective of Specific Aim 3 
was to determine whether central IL-6 alone or in the presence of other known 
secretagogues was sufficient to stimulate or augment glucagon secretion.  
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Specific Aim 3a: The objective of this sub aim was to determine whether IL-6 
alone or in the presence of known glucagon secretagogues is sufficient to enhance 
glucagon secretion from islets. Islets were isolated from IL-6 knock-out mice (thus 
avoiding endogenous IL-6 production) and underwent pancreatic perifusion studies to 
determine whether IL-6 could augment glucagon secretion alone or in the presence of 
arginine or epinephrine, two known (and potent) glucagon secretagogues. Importantly, 
epinephrine is elevated under various physiological or pathophysiological settings of 
stress. While we did not look at the direct impact that LPS might have on IL-6-mediated 
glucagon secretion, it is important to realize that elevated epinephrine is one index of 
the impact of stress on the islet.  
Specific Aim 3b: Specific Aim 3a demonstrated that IL-6 augments epinephrine-
stimulated glucagon secretion. Therefore, the objective of this sub aim was to determine 
whether IL-6 enhances epinephrine-stimulated glucagon secretion via a calcium-
dependent mechanism.  
 
Hypothesis 
 
Although others have previously demonstrated that IL-6 can act directly on the 
pancreas to increase glucagon transcription and secretion, the effects of this cytokine 
were found to be slow and happened over several hours. In studies previously 
published from the McGuinness lab, IL-6 infusion had a rapid effect on modulating the 
glucagon response to lipopolysaccharide. Therefore, the overarching hypothesis for this 
work was that IL-6 enhances glucagon secretion predominantly via the brain.   
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CHAPTER II: MATERIALS AND METHODS 
 
Animal Care and Usage 
 
 
Ethics Statement 
 
All animal procedures were performed with approval of the Institutional Animal 
Care and Usage Committee of Vanderbilt University. The NIH guidelines for the care 
and use of laboratory animals were followed.  
 
Animal Care and Husbandry 
 
Mice were group housed in micro-isolater cages in a temperature and humidity-
controlled room with a 12:12 hour light/ dark cycle. At the time of surgery, mice were 
individually housed in clean cages. Mice were maintained on a standard rodent chow 
diet purchased from Research Diets, Inc. (New Brunswick, NJ) and were fed ad libitum 
with free access to water. All in vivo studies were performed on mice that were handled 
extensively on a daily basis from the time of initial surgery to reduce the contribution of 
stress to these studies. Mice that were cannulated also were prepared for the morning 
of study by loosening and tightening the dummy cannula for two days leading up to the 
experiment (see Cannulation below).  
 
Mice Used in Lateral Ventricle Injection Studies and Perifusion Studies 
 
Male IL-6−/− (IL-6 knock-out) mice on a C57Bl/6 background (B6.129S2-
Il6tm1Kopf/J) were purchased from Jackson Laboratories (Bar Harbor, ME) at 10 weeks of 
age. All surgeries and experiments were performed on 12-14 week old mice. IL-6 
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knock-out mice at this age do not become obese and have not yet developed the 
obesity-associated complications characterized in older mice (141).  
 
Mice Used in Pharmacologic Blockade Studies 
 
These studies used wild-type (C57Bl/6) mice bred in our in-house colony 
(originally from Jackson Laboratories, Bar Harbor, ME). Mice were between 12-14 
weeks of age at the time of the experiment. At three weeks of age, these mice were 
weaned and separated by gender and subsequently fed standard rodent chow. 
 
 
Mice Used in Alpha Cell Calcium Studies 
 
For the islet calcium imaging studies, mice (C57Bl/6 background) expressing 
tandem dimer red fluorescent protein tdRFP under control of the proglucagon promoter 
(72) were used.  
 
Surgical Procedures 
 
All surgeries were performed in 12-14 week-old mice. At the time of surgery, 
mice were separated and maintained in micro-isolator cages on a 12-h light/dark cycle 
with free access to food and water. Mice were handled extensively on a daily basis 
following surgery to minimize stress on the day of the experiment. 
 
 
Cannulation 
 
Cannulation surgeries were performed one week prior to catheterization surgery 
to allow mice to fully recover between surgeries. Surgical setups as well as the 
surgeries themselves were performed aseptically. Mice were anesthetized using 
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isoflurane and prepped for surgery by shaving the head and washing the area with 
ethanol.  
The mouse was connected to a Stoelting Stereotaxic Frame (Kiel, WI), using ear 
bars and incisor bar to properly set the cranium in place for cannulation. In this 
stereotaxic setup, the incisor bar fits into a nose cone that allows for isoflurane to flow 
through the system to maintain anesthesia throughout the procedure. A single incision 
was made down the center of the skull from ~0.5 cm posterior to the eyes to lambda on 
the mouse skull. This incision is large enough to access the required area as well as set 
screws in place but small enough that minimal suturing is necessary. The area was 
rinsed with warm saline, and the meninges were pushed sideways to expose the skull. 
Following exposure of the skull, proper orientation in the stereotaxic frame was 
assessed; ear bar platforms were raised or lowered to assure that the skull was in a 
level position. Before placing the guide cannula, skull screws (PlasticsOne, Roanoke, 
VA) that would ultimately anchor the guide cannula were placed. First, a small hand drill 
(PlasticsOne) was used to make 3 separate holes to house the screws. The holes were 
placed away from capillary beds and away from the area where the guide cannula 
would be placed. Any bleeding was stopped by pressing a sterile cotton applicator 
against the affected area (Note: bleeding was usually very minimal). The screws were 
carefully screwed in place; they were not screwed in completely to avoid cortical 
damage.  
Following screw implantation, the guide cannula (held in place by the stereotaxic 
frame) was carefully lowered to meet Bregma. The cannula (PlasticsOne) was then 
raised and moved to the desired location for cannulation (coordinates: 0.6 mm posterior 
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to bregma, 1.5 mm lateral to midline). A Dremel drill with a sterile drill bit was used to 
make a small hole at this location; any minimal bleeding was stopped again using a 
cotton applicator). The guide cannula was lowered to the surface of the skull and then 
slowly and carefully lowered to the desired depth (1.4 mm below the surface of the 
skull).  
Once the guide cannula was lowered, FujiCEM glass ionomer cement (Instech, 
Plymouth Meeting, PA) was applied to the area to secure cannula placement. The 
cement was spread around all the skull screws as well as around the guide cannula. 
The cement was allowed to dry, and a dummy cannula (PlasticsOne) was subsequently 
screwed in place. The mouse was sutured to close any exposed region of the skull and 
given an intraperitoneal bolus of ketoprofen per Vanderbilt Institutional Animal Care and 
Use Committee guidelines for analgesia. Following surgery, mice were individually 
housed in clean cages. Successful cannulation was assessed following the experiment 
by cryosection or using methylene blue dye injection.  
Post-operative measures were taken to ensure that each rodent recovered 
following surgery. Included in the care was monitoring the daily body weight of the 
mouse following surgery (this was done at the same time handling was done) as well as 
maintaining the mouse on a heating pad for a minimum of two days following surgery. 
Mice were also observed for any abnormal behavior cues that would suggest 
discomfort/complications following the surgery.  
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Catheterization 
 
Mice were first anaesthetized with isoflurane. The setup for surgery as well as 
the surgical process utilized aseptic technique. While under anaesthesia, mice were 
prepared for surgery by shaving around the surgical site. The area was subsequently 
washed with ethanol and betadine scrub.  
  An incision was first made 5 mm cephalic to the sternum, and the left 
sternomastoid muscle was exposed. The sternomastoid muscle was reflected, to reveal 
the left carotid artery. The connective tissue and vagus nerve were then separated from 
the vessel. A silk suture was tied at the cephalic end and another loosely knotted on the 
caudal end of the carotid. The artery was clamped with micro- serrefine and cut just 
below the ligated end and the catheter was inserted until the tip reached the aortic arch. 
The ligatures were secured and catheter sampling confirmed. 
An incision was made 5 mm to the right of the midline and 2 mm caudal to the 
incision for the carotid catheter. The jugular vein was isolated and ligated at the cephalic 
end with a loose knot at the caudal end similar to the carotid catheter. The catheter for 
the jugular vein was inserted after a small incision and flushed to ensure patency.  
A third incision was made between the shoulder blades of each mouse and a 14- 
gauge needle was tunneled under the skin. The catheters (carotid and jugular) were 
threaded through the needle to tunnel out of the back of the mouse. The ventral 
incisions were closed with a nylon suture. The arterial catheter was clamped with micro- 
serrefine at the incision site between the shoulder blades. The catheter was cut 1 cm 
above the clamp and connected to the MASA™ with a silk suture and repeated for the 
either the venous or gastric catheter. The dorsal incision was closed with silk sutures. 
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The animal was individually housed in a clean cage after this surgical procedure. 
Post-operative measures were similar to those described following cannulation 
surgery. Surgical procedures as well as the post-operative care regimen are published 
and described within the Vanderbilt Mouse Metabolic Phenotyping Center website 
(www.vanderbilt.edu/mmpc), and a video by Ayala and colleagues is also available (4).  
 
In vivo Metabolic Experiments 
 
All in vivo metabolic experiments were performed following a ~5-day post-
operative recovery period. Animals were studied only if they were within 10% of their 
pre-surgery body weight. Conscious, unrestrained mice were placed in ~1-L plastic 
container lined with bedding (7:00 am) and fasted for 5 hours to ensure that all mice 
were in the post-absorptive phase during study. Approximately 2 hours prior to the 
experiment, animals were connected to a Dual Channel Stainless Steel Swivel (Instech 
Laboratories, Plymouth Meeting, PA.) to allow for free movement, while being able to 
simultaneously infuse via the jugular vein and sample through the carotid artery, as well 
as microinfuse into the lateral ventricle. To prevent a fall in hematocrit due to sampling, 
an infusion of donor red blood cells was begun 1 hour prior to the experiment and 
continued for the duration of the study. The hyperinsulinemic-hypoglycemic clamp and 
LPS studies utilized IL-6 knock-out mice (Jackson Labs) and were performed in 
catheterized and cannulated mice, while wild-type mice used in the ganglionic blockade 
and sympathetic/parasympathetic antagonist studies were catheterized only. All mice 
were handled extensively to minimize stress on the day of the experiment. At the end of 
all studies, mice were sacrificed via a lethal dose of sodium pentobarbital (IV). 
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Central IL-6 and Lipopolysaccharide 
 
Twenty minutes prior to the start of the experiment (t = -20), a baseline arterial 
blood sample was drawn for measurement of blood glucose, hematocrit, plasma insulin, 
and plasma glucagon. At t= -10 min, a microinjection of 2 µL of bacteriostatic saline 
(vehicle control) or 200 ng recombinant mouse IL-6 (Biomyx, San Diego, CA) was 
administered (100 ng/µL IL-6 at 1 µL/min for 2 min) via the lateral ventricle cannula 
using a microinfusion pump and a Hamilton microinfusion syringe (Hamilton, Reno, NV). 
At t= 0 min, either saline or 1 mg/kg lipopolysaccharide (LPS, Sigma Aldrich, St. Louis, 
MO) dissolved in saline was administered as a bolus via the jugular vein. Arterial blood 
was sampled at 10-minute intervals to assess the glucose response. Plasma was taken 
at t= 60 and 120 min for glucagon measurement and at t= 120 for insulin. A basal and 
terminal plasma sample was also taken for plasma catecholamines; however, the 
samples were compromised and lost in the assay procedure.  
 
 
Sympathetic/Parasympathetic Blockade and LPS 
 
Thirty minutes prior to the start of the experiment (t= -30), a baseline arterial 
blood sample was drawn for measurement of glucagon and at t= -25 min for baseline 
plasma insulin. Ten minutes prior to LPS bolus, (t= -10), mice were given either 1) 
phentolamine and propranolol (2 mg/kg priming bolus for both followed by a 0.02 
mg/kg/min intravenous infusion for the duration of the study) to block alpha and beta 
adrenergic receptors, respectively, 2) atropine (1 mg/kg prime followed by 0.01 
mg/kg/min intravenous infusion for the duration the study) to block muscarinic 
cholinergic receptors, or 3) saline.  At t= 0 min, 1 mg/kg LPS was given as a bolus via 
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the jugular vein. For all groups of mice, arterial blood was sampled at 20-minute 
intervals to assess the glucose response. Plasma was taken at t= 60 and 100 min for 
glucagon measurement and at 120 min for insulin. Basal and terminal plasma was also 
sampled for catecholamines; however, the samples were also compromised and lost in 
the assay procedure. 
 
Ganglionic Blockade and LPS 
 
A baseline sample was taken for assessment of glucagon (t= -20 min). At t= -30 
min, mice were given a bolus of 12 mg/kg chlorisondamine diiodide (Sigma Aldrich, St. 
Louis, MO) or saline as a control. At t= 0 min, 1 µg/g LPS was given as a bolus via the 
jugular vein. For both groups of mice, arterial blood was sampled at 20-minute intervals 
to assess the glucose response. Plasma was taken at t= 60 and 120 min for glucagon 
measurement. Since chlorisondamine decreases blood pressure, the carotid artery 
catheter was connected to a blood pressure monitor (via a Y connector at the carotid 
artery catheter) to ensure efficacy of the chlorisondamine bolus; successful ganglionic 
blockade reduced mean arterial pressure by ~50 mmHg.  
 
Hyperinsulinemic-Hypoglycemic Clamp 
 
Prior to onset of hyperinsulinemia or microinjection into the lateral ventricle, 
baseline arterial plasma samples were taken for assessment of glucagon (t= -30 min), 
insulin (t= -25 min), or catecholamines (t= -20 min). Ten minutes prior to the start of 
hypoglycemia, a 2 µL microbolus of either bacteriostatic saline (vehicle control) or 200 
ng recombinant mouse IL-6 was infused at a rate of 1 µL/min for 2 minutes (as 
described above). At t= 0, a constant jugular vein infusion of insulin (10 mU·kg-1·min-1) 
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was begun, and a variable amount of glucose (20% dextrose) was administered to 
target   or   “clamp”   the   blood   glucose   at   approximately   60   mg/dl.   Blood   glucose   was  
monitored at 10-minute intervals. Arterial plasma was taken at t= 30, 60, and 120 min to 
assess plasma glucagon. A terminal arterial sample was also taken to assess plasma 
insulin and catecholamines (t= 120 min). 
 
Plasma Collection and Measurements  
 
For all in vivo studies, arterial blood was drawn from catheterized mice and 
placed into EDTA-containing microcentrifuge tubes. The tubes were subsequently spun 
1 minute at 12,000 r.p.m. Plasma was collected into tubes and stored at -80oC until 
analysis. The Vanderbilt Hormone Assay and Analytical Services core assayed 
glucagon, insulin, and catecholamines. Immunoreactive insulin and glucagon were 
assayed using a Rat Radioimmunoassay kit (EMD Millipore, Ballerica, MA) using a 
double antibody method. Catecholamines were assessed using HPLC with 
electrochemical detection following alumina extraction and subsequent elution (3, 78). 
Plasma IL-6 was assessed using ELISA (Millipore, Ballerica, MA). For collection of 
blood   for   glucagon   analysis,   2   μL   trayslol   was   put   into   EDTA   tubes   prior   to   blood  
collection. For collection of blood for catecholamine analysis, 2  μL  of  glutathione/EGTA  
was put into EDTA tubes prior to blood collection.  
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Ex vivo Experiments 
 
Islet Isolation and Perifusion 
 
Islet isolation and perifusion were performed with the help of the Vanderbilt Islet 
Procurement and Analysis Core. IL-6 knock-out mice were anesthetized via 
intraperitoneal injection of a mixture of ketamine and xylazine (80 and 20 mg/kg, 
respectively), and islets were isolated as previously described (15). Briefly, islets were 
separated from exocrine tissue by density gradient centrifugation (Histopaque and 
RPMI, Sigma-Aldrich,   St.   Louis,   MO).   Puriﬁed   islets   were   then   hand-picked and 
maintained free-ﬂoating   in   islet   culture   medium:   RPMI   with   added   D-glucose 
(concentrations varied as described below), L-glutamine (2mM; Sigma-Aldrich), 
ascorbic acid (0.7 mg/mL; Sigma-Aldrich), benzyl penicillin (100 U/mL, Roche 
Diagnostics), streptomycin (0.1 mg/mL), and 10% (volume/volume) fetal calf serum 
(Sigma-Aldrich). The ability of IL-6 to modulate glucagon secretion was examined in the 
dynamic cell perifusion system (15). One hundred islet equivalents were placed in a 
chamber and washed with baseline media (5.6 mM glucose) for 30 minutes prior to the 
experiment. Islets were perfused for 9 minutes with multiple secretagogues of glucagon, 
preceded each time by a 9-minute washout period with 5.6 mM glucose-containing 
buffer. Islets were perfused with secretagogues in the following order: 1) 1.7 mM 
glucose, 2) 1.7 mM glucose + 200 ng/ml recombinant mouse interleukin-6  (IL-6; 
Biomyx, San Diego, CA), 3) 1.7 mM glucose + IL-6 + 1 µM epinephrine, and finally 4) 
1.7 mM glucose + IL-6 + 20 mM arginine. The effluent fractions were collected at 3-
minute intervals using an automatic fraction collector. The glucagon content of each 
fraction was assessed by radioimmunoassay. 
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Islet Isolation and Calcium Imaging 
 
Islets were isolated and imaged from mice expressing tdRFP under control of the 
proglucagon promoter as previously described (72). Islets   were   incubated   with   5   μM  
Fluo4-AM for 30 minutes at 2.8 mM glucose. After washing, islets were placed in a 
microfluidic device (106) and allowed to equilibrate on the microscope stage for 15 
minutes in the same solution.  Islets were exposed to low glucose (1.7 mM), low 
glucose + epinephrine (1 uM), low glucose + IL-6 (200 ng/ml), or low glucose + IL-6 + 
epinephrine. Fluo-4 was excited at 488 nm and detected between 495 and 545 nm.  
Red alpha cells were localized by recording tdRFP fluorescence excited by 561 nm.  
Time courses were collected with an LSM780 (Carl Zeiss) using a Fluar 40x/1.3NA lens 
and a 2 Airy unit pinhole. Mean intensities were normalized to the first 5 frames of data 
8 minutes following reagent change.  
 
Statistical Analysis  
 
SigmaPlot 12.0 software was used for all statistical analyses. All data are 
presented as mean ± SEM. All in vivo data were analyzed using two-way repeated 
measures ANOVA followed by Bonferroni post-hoc test as appropriate. Perifusion data 
and  calcium   imaging  data  were  analyzed  using  Student’s   t-test. The significance level 
was set at p < 0.05. 
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CHAPTER III: INTERLEUKIN-6 ENHANCES GLUCAGON SECRETION VIA THE 
BRAIN IN SETTINGS OF STRESS AND VIA THE PANCREAS IN SETTINGS OF 
ELEVATED ADRENERGIC TONE 
 
(Adapted from Barnes et al. (2014). Am J Physiol Endocrinol Metab.  
Nov 15: 307 (10): E896-905.) 
 
Aims 
 
The primary goal of Chapter III was to determine whether interleukin-6 (IL-6) 
could modulate glucagon secretion via the brain either alone (Specific Aim 1a) or during 
a setting of inflammatory stress (Specific Aim 1b). Previous work from the McGuinness 
lab demonstrated that IL-6 deficient (IL-6 knock-out) mice have a blunted glucagon 
response to acute inflammation (lipopolysaccharide, LPS) compared to their wild-type 
littermates. The glucagon response is completely rescued by intravenous replacement 
of IL-6 (133). In those studies, other pro-inflammatory cytokines (e.g. TNF-alpha and IL-
1 beta) increased normally following LPS administration, suggesting a specific role for 
IL-6 in modulating the acute effect on glucagon secretion. IL-6 may also have longer-
acting  effects  on  α-cells; human islets incubated for 4 or 24 hours in the presence of IL-
6 exhibited increased glucagon secretion and proglucagon expression compared to 
untreated controls (34). The glucagon response that was observed in our previous 
studies was much more rapid. Therefore, knowing that IL-6 can cross the blood-brain 
barrier (5) as well as be produced within the brain (36), and that IL-6 receptors are 
expressed rather ubiquitously throughout the brain (137), we hypothesized that the 
rapid glucagon secretory response to LPS was due to direct actions within the brain, 
which in turn augmented autonomic drive to the islet. 
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To address this hypothesis, we utilized IL-6 knock-out mice and followed an 
approach based on our historic literature; mice were catheterized and given an 
intravenous bolus of LPS to stimulate glucagon secretion (6). The novelty in our 
approach was that mice were also cannulated in the lateral ventricle. In previous 
studies, IL-6 was administered intravenously, whereas in these studies, IL-6 was 
administered only into the lateral ventricle. Thus, the results of these findings would 
demonstrate whether IL-6 stimulates glucagon secretion when it is administered only 
centrally. Because we had not yet characterized the effect of central IL-6 alone (in the 
absence of inflammation), we also studied the effect of central IL-6 injection alone in 
another cohort of mice. Additionally, to determine if central IL-6 plays a role in an 
alternative setting of stress (hypoglycemia), an additional cohort of mice underwent 
hyperinsulinemic-hypoglycemic clamps (Specific Aim 1c). Utilizing IL-6 knock-out mice 
allowed for us to rule out production of endogenous IL-6, which could complicate the 
interpretation of our results. These studies would function to determine whether central 
IL-6 alone was sufficient to augment the glucagon response to LPS and whether central 
IL-6 had an effect on glucagon secretion in the absence of inflammation.  
Further studies were also conducted in wild-type mice to pharmacologically 
determine the contribution of the sympathetic and parasympathetic branches of the 
autonomic nervous system (ANS) to the glucagon response to LPS (Specific Aim 2). 
The intent for these studies was to determine if one branch of the ANS may 
predominate in modulating glucagon secretion following LPS; if one branch was found 
to be unnecessary for the glucagon response, then perhaps this branch is not the one 
through which central IL-6 may operate to enhance glucagon secretion.  
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Importantly, demonstrating that a central effect of IL-6 does not rule out that IL-6 
modulates glucagon secretion from the islet in a more rapid manner than previously 
observed (34). A series of ex vivo studies examined the role of IL-6 on acute glucagon 
secretion from islets to determine if IL-6 alone or in a setting of simulated stress 
(elevated epinephrine) could augment glucagon secretion (Specific Aim 3).  
 
Introduction 
 
Inflammatory disease causes profound alterations in glucose homeostasis and 
accompanying insulin resistance. Exquisite control of insulin And glucagon secretion 
from the pancreas maintains euglycemia in healthy individuals (143). However, this 
balance is altered in inflammatory disease. The bulk of glucoregulatory research has 
focused on the insulin side of the story for some years, while less research has focused 
on therapies to attenuate glucagon secretion or action. Demonstrating the importance of 
glucagon, hyperglycemia associated with insulin deficiency does not manifest in the 
absence of glucagon-dependent signaling in rodent models of diabetes (73). Moreover, 
in models of type 2 diabetes, inhibition of glucagon also improves glucose homeostasis 
(119). While diabetes and acute or chronic inflammation are vastly different in etiology 
and pathology, they have some similarities: hyperglycemia is associated with either a 
rise in absolute levels of glucagon or in the ratio of glucagon-to-insulin as well as in pro-
inflammatory cytokines. Moreover, improving glycemic control improves patient 
morbidity and mortality (60, 85, 139). Therefore, understanding the mechanisms that 
cause inappropriate glucagon secretion is critically important for developing treatment 
strategies to improve glucose homeostasis in inflammatory disease.  
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IL-6 is a cytokine with a variety of physiologic roles. IL-6 acts in adipose tissue to 
stimulate lipolysis and inhibit insulin action on glucose transport and lipogenesis. In 
muscle, IL-6 stimulates fat oxidation and glucose uptake. Further, IL-6 stimulates 
glucose production from liver and inhibits insulin action on glycogen synthesis (114). IL-
6 has also been well established as both a pyrogen (via HPA axis activation) and a 
stimulator of the acute-phase protein response via the liver. Previous work has 
demonstrated a role of the pro-inflammatory cytokine, interleukin-6 (IL-6) in modulating 
glucagon secretion. Plasma IL-6 is elevated in physiologic and pathophysiologic 
settings where glucagon is also elevated: exercise (100), diabetes (7), and inflammatory 
stress (55). Furthermore, IL-6 has become implicated in metabolic disease as a 
predictive factor in the development of type 2 diabetes (121). Our previous data 
demonstrated that IL-6 acutely modulates glucagon secretion in vivo during acute 
inflammation. Herein, we tested whether IL-6 exerts its actions via the brain, islets, or 
both. In this dissertation, I have demonstrated that central IL-6 augments glucagon 
secretion, but it does so only in the presence of an accompanying stressor, be it acute 
inflammation or hypoglycemia. These data suggest a potent modulatory role for this 
cytokine. Contrary to my original hypothesis, I found that IL-6 also amplifies acute 
glucagon secretion from isolated islets in the presence of an accompanying stressor. 
These data provide insight into the dual role of IL-6 in amplifying neural drive to the 
pancreas and increasing the effectiveness of adrenergic signaling at the islet to 
stimulate glucagon secretion. 
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Results 
 
 
Central Interleukin-6 enhances glucagon secretion during acute inflammation in IL-6 
knock-out mice 
To determine whether central IL-6 signaling modulates glucagon secretion, 
chronically catheterized, cannulated IL-6 knock-out mice were microinjected with IL-6 or 
vehicle (Veh) via the lateral ventricle. As acute inflammation is a potent stimulator of 
glucagon secretion, separate cohorts of mice were exposed to intravenous 
lipopolysaccharide (LPS; 1 mg/kg, IV) to determine whether central IL-6 could augment 
LPS-stimulated glucagon secretion (Figure 3.1). IL-6 knock-out mice were used to 
avoid endogenous production of IL-6 that might confound interpretation of these studies. 
 
 
 
Figure 3.1: Time-course of IL-6 lateral ventricle injection study. Mice that were 
5 h fasted were administered a microbolus of IL-6 or vehicle 10 minutes prior to an 
IV bolus of either LPS or saline. To compensate for loss of blood, mice were 
administered donor blood beginning 60 minutes prior to the start of the experiment 
and continuing throughout the study. Arterial blood was collected over time to 
monitor changes in glucose, and plasma was collected over time to monitor 
changes in glucagon and insulin. 
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IL-6 knock-out mice experienced no change in plasma glucagon in response to 
IL-6 microinjection alone (54±11 vs. 49±5 pg/ml at 120 minutes; Veh vs. IL-6 injection) 
(Figure 3.2A). In contrast, central IL-6 microinjection nearly doubled circulating 
glucagon by 120 minutes when mice were administered LPS (85±14 vs. 143±12 pg/ml; 
Veh vs. IL-6 injection). LPS administration slightly elevated plasma glucose levels 
throughout the period of study (Figure 3.2B), but central IL-6 did not further modulate 
the glucose response. There were no differences observed between groups in plasma 
insulin prior to or 2 hours following either LPS/saline injection (Figure 3.2C). IL-6 did not 
escape the central nervous system, as circulating IL-6 concentrations were 
undetectable following central IL-6 administration. Consistent with the data found here 
in IL-6 knock-out mice, in a small cohort of wild-type mice, central IL-6 injection alone 
did not enhance glucagon secretion at any time point observed (t= 0 min, 56±6 vs. 
64±6; t= 30 min, 64±14 vs. 59±6; t= 60 min, 50±0 vs. 68±7 pg/ml; Veh vs. IL-6 injection). 
These results provide evidence in IL-6 knock-out mice that IL-6 acutely modulates 
glucagon secretion via the brain, but interestingly, it does so only in the presence of an 
accompanying stressor such as LPS.  
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The sympathetic and parasympathetic nervous systems drive LPS-stimulated glucagon 
in wild-type mice 
 
While data support the involvement of the autonomic nervous system (ANS) in 
the glucagon response to hypoglycemia (50, 51, 128), the role of the ANS in the 
glucagon response to LPS is yet to be elucidated. Activation of both the sympathetic 
and parasympathetic nervous system can stimulate glucagon secretion. Therefore, 
understanding if one branch predominates in the response to LPS could inform our 
grasp of how central IL-6 signaling influences autonomic drive. To determine the role of 
each branch of the ANS in the glucagon response to LPS, chronically catheterized, 5-
Figure 3.2: Central IL-6 augments the glucagon response to endotoxin. 
Chronically catheterized, cannulated IL-6 knock-out mice were administered either IL-
6 or vehicle (Veh) into the lateral ventricle (LV) prior to IV injection of 
lipopolysaccharide (LPS) or saline. Plasma glucose (Panel A), GCG (Panel B), and 
insulin (Panel C) were assessed over time. n= 5-7 mice/group.      * = p < 0.05 
relative to both LV Veh, Saline and LV Veh, LPS treatments. ¥= p < 0.05 relative to 
LV Veh, Saline.  
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hour fasted wild-type male mice were pre-treated with pharmacologic antagonists of 
either the sympathetic nervous system or parasympathetic nervous system followed by 
exposure to LPS (1 mg/kg, IV). To target the sympathetic nervous system (SNS), 
combined alpha and beta-adrenergic receptor blockade with phentolamine and 
propranolol, respectively, was employed. The parasympathetic nervous system (PNS) 
was targeted using muscarinic cholinergic receptor blockade with atropine (Figure 3.3).  
 
  
 
 
 
Pharmacologic blockade of the SNS but not PNS resulted in a rapid fall in blood 
glucose in response to LPS administration (Figure 3.4A). Interestingly, however, the 
LPS-induced glucagon response was blunted following both sympathetic blockade (SB) 
and parasympathetic blockade (PB) (129±4 vs. 59±8 vs. 74±6 pg/ml at 120 min; control 
Figure 3.3: Time-course of adrenergic blockade study. Mice that were 5 h 
fasted were administered a primed continuous infusion via the jugular catheter of 
pharmacologic antagonists of the sympathetic nervous system (combined 
adrenergic blockade with propranolol and phentolamine) or of the 
parasympathetic nervous system (atropine). After beginning the infusion (10 min), 
a bolus of LPS was administered IV. To compensate for loss of blood, mice were 
administered donor blood beginning 60 minutes prior to the start of the 
experiment and continuing throughout the study. Arterial blood was collected over 
time to monitor changes in glucose, and plasma was collected over time to 
monitor changes in glucagon, insulin, and IL-6. 
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vs. SB vs. PB) (Figure 3.4B). No differences in terminal plasma insulin were observed 
(Figure 3.4C). Terminal plasma was also assessed for IL-6 levels. Neither adrenergic 
blockade nor cholinergic blockade had an effect on terminal plasma IL-6 compared to 
controls (Figure 3.4D). Despite the hypoglycemic (and thus further glucagon-
stimulating) environment in mice with SB, plasma glucagon levels were blunted even 
greater than mice with PB. This suggests that while both branches of the ANS mediate 
the glucagon secretory response to LPS, the SNS plays the predominant role. 
 
 
Figure 3.4: Both the sympathetic and parasympathetic nervous systems are 
involved in the glucagon response to LPS. Chronically catheterized wild-type 
mice were administered (IV) parasympathetic blocker (PB), sympathetic blockers 
(SB), or saline (Control). Mice were then administered LPS. Blood glucose (Panel 
A) and plasma GCG (Panel B) were assessed over time. Terminal plasma insulin 
(Panel C) and IL-6 (Panel D) were also assessed. n= 6 mice per group. * = p < 0.05 
relative to control. ¥= p < 0.05 relative to PB. 
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Neural drive is necessary for the glucagon response to LPS in wild-type mice 
To further determine the role of neural drive in the glucagon response to LPS, 
chronically catheterized, 5 hour fasted wild-type mice were exposed to ganglionic 
blocker (12 mg/kg chlorisondamine, IV) or saline control and subsequently treated with 
LPS (1 mg/kg) (Figure 3.5). 
  
 
 
 
 
No significant difference in blood glucose levels was observed throughout the 
study between treatments (Figure 3.6A). Mice treated with ganglionic blocker (GB) 
failed to increase glucagon in response to LPS (Figure 3.6B), with the effect most 
pronounced at the end of the study (126±14 vs. 51±7 pg/ml; control vs. GB). GB 
suppressed plasma glucagon even prior to administration of LPS (t= 0; 68±15 vs. 46±5 
Figure 3.5: Time-course of ganglionic blockade study. Mice that were 5 h 
fasted were administered a jugular bolus of the ganglionic blocker, chlorisondamine 
(or saline as a control). After the bolus (30 min), LPS was also administered via the 
jugular vein. To compensate for loss of blood, mice were administered donor blood 
beginning 60 minutes prior to the start of the experiment and continuing throughout 
the study. Arterial blood was collected over time to monitor changes in glucose, and 
plasma was collected over time to monitor changes in glucagon, insulin and IL-6. 
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pg/ml; control vs. GB), supporting the role of the ANS in modulating glucagon levels, 
even in the non-stimulated, resting state. Interestingly, GB also blunted the LPS-
induced rise in plasma IL-6 (175±25 vs. 37±11 ng/ml; control vs. GB) (Figure 3.6C); this 
was not observed with either sympathetic or parasympathetic blockade alone (Figure 
3.4D). The IL-6 response was not abolished by ganglionic blockade, however, as IL-6 
levels are <0.007 ng/ml in the absence of LPS. These results suggest that neural drive 
is needed for not only the glucagon response, but also for a robust IL-6 response to 
LPS.  
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Central Interleukin-6 augments the glucagon response to hypoglycemia in IL-6 knock-
out mice 
Prior work indicates the importance of the CNS for a full counter-regulatory 
(glucagon, epinephrine) response to hypoglycemia (127). Knowing that plasma IL-6 
levels rise during hypoglycemia (30), we sought to determine whether central IL-6 could 
modulate glucagon secretion in response to this alternative stressor. Chronically 
catheterized, cannulated IL-6 knock-out mice underwent hyperinsulinemic/hypoglycemic 
clamps (Figure 3.7).  
Figure 3.6: Autonomic drive is necessary for the glucagon response to LPS.  
Chronically catheterized wild-type mice were given a jugular bolus of a ganglionic 
blocker (GB), or saline (Control). Mice were subsequently administered LPS. Blood 
glucose (Panel A) and plasma GCG (Panel B) were assessed over time. Terminal 
plasma IL-6 (Panel C) was also assessed. n= 6 mice per group. * = p < 0.05 
relative to control. 
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The rate of fall in blood glucose and the absolute glucose levels during 
hypoglycemia were well matched between vehicle (Veh) and IL-6-microinjected mice, 
allowing for proper comparison of counter-regulatory response (Figure 3.8A). By 20 
minutes of hypoglycemia, the target glucose was reached and was maintained 
throughout the clamp period. No differences were observed in baseline glucagon 
(Figure 3.8B), but when IL-6 was administered centrally, there was a significant 
increase in plasma glucagon (t= 30 min) in mice treated with central IL-6 (95±15 vs. 
137±17 pg/ml; Veh vs. IL-6). This trend was maintained throughout the clamp study. 
Plasma insulin concentrations were similar at baseline and rose similarly during the 
Figure 3.7: Time-course of hyperinsulinemic-hypoglycemic clamp study. Mice 
that were 5-hour fasted were administered a microbolus of IL-6 (or vehicle control) 
10 minutes prior to the start of the hypoglycemic clamp. During the clamp, a 
continuous jugular infusion of insulin (10 mU/kg/min) and a variable infusion of 20% 
dextrose   was   administered   to   “clamp”   blood   glucose   around   50   mg/dl.   To  
compensate for loss of blood, mice were administered donor blood beginning 60 
minutes prior to the start of the experiment and continuing throughout the study. 
Arterial blood was collected over time to monitor changes in glucose, and plasma 
was collected over time to monitor changes in glucagon, insulin, and 
catecholamines. 
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clamp; Figure 3.8C). Catecholamine levels were not different between treatment groups 
(Figure 3.8D and 3.8E). Thus, centrally administered IL-6 enhances the glucagon 
response to insulin-induced hypoglycemia without amplifying circulating epinephrine 
and norepinephrine. These data provide evidence that IL-6 augments glucagon 
secretion during multiple stressors.  
 
 
 
Figure 3.8: Central IL-6 augments the glucagon response to hypoglycemia. 
Chronically catheterized, cannulated IL-6 knock-out mice were given either IL-6 or 
vehicle (Veh) into the lateral ventricle (LV) prior to onset of insulin-induced 
hypoglycemia (10 mU/kg/min). Blood glucose (Panel A) and plasma GCG (Panel 
B), insulin (Panel C), epinephrine (Panel D; Epi), and norepinephrine (Panel E; 
Norepi) were also assessed. n= 6-7 mice per group.  * = p < 0.05 relative to control. 
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IL-6 enhances epinephrine-stimulated glucagon secretion from IL-6 knock-out islets 
While studies have examined longer-term transcription-related effects of IL-6 on 
glucagon secretion, none have yet characterized the acute action of the cytokine at 
islets. A dynamic islet perifusion system was used to determine whether IL-6 acutely 
modulates glucagon secretion from the pancreas. Islets isolated from IL-6 knock-out 
mice were used to avoid the contribution of endogenous IL-6 to the studies. Islets were 
perfused with media containing 200 ng/ml IL-6 or vehicle and known glucagon 
secretagogues. 
 
 
 
Figure 3.9: IL-6 enhances the epinephrine-stimulated glucagon response in 
isolated islets. IL-6 knock-out islets were isolated and perfused in a cell perifusion 
system with 1.7 mM glucose either alone (Lo) or with 1 µM epinephrine (Epi) or 20 
mM arginine (Arg). Half of the islets received concurrent IL-6 exposure (200 ng/mL). 
A 5.6 mM glucose wash was performed between secretagogue exposures. Fractions 
were collected over time and analyzed for glucagon and insulin. Panel A: time-course 
of glucagon and insulin over various secretagogue exposures. Panel B: AUC values 
from time-course (pg/islet equivalent). * = p < 0.05 relative to control. 
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IL-6 had no effect on glucagon secretion in low glucose (1.7 mM) media (Fig. 
3.9A). Surprisingly, however, in the presence of low glucose plus 1 µM epinephrine, IL-6 
enhanced the glucagon response (765±76 vs. 1017±55 pg glucagon/ islet equivalents), 
suggesting a potential interaction between the IL-6 and catecholamine signaling 
pathways to increase glucagon secretion. IL-6 did not enhance arginine-stimulated 
glucagon secretion. Since insulin can inhibit glucagon secretion, the concentration of 
glucose in the perfusate was kept low in these studies to inhibit insulin release; none 
was detectable for all treatments.  
To verify that IL-6 knock-out islets have a similar glucagon-secreting capacity as 
wild-type islets, a separate experiment was conducted using the same secretagogues 
and concentrations (in the absence of IL-6). We found that glucagon secretion was 
similar in both wild-type and IL-6 knock-out islets in response to secretagogues (Figure 
3.10). These data demonstrate that IL-6 modulates glucagon secretion from islets in the 
presence of adrenergic (epinephrine) signaling but not independently. 
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Synergy between IL-6 and epinephrine signaling is calcium-independent 
 
To determine whether IL-6 may augment epinephrine-stimulated glucagon 
secretion via a global intracellular Ca2+ ([Ca2+]i)-dependent mechanism, islets were 
isolated from mice with tdRFP-expressing  α-cell (72), and subsequently loaded with the 
calcium (Ca2+) indicator dye, Fluo-4. Using a microfluidic device (106), Fluo-4 intensity 
was monitored over time in islets from 4 mice treated first with 1.7 mM glucose and 
subsequently switched into 1.7 mM glucose buffer containing IL-6 (200 ng/ml), 
epinephrine (1 µM), or both.   
 
Figure 3.10: IL-6 knock-out and wild-type islets respond similarly to known 
secretagogues. IL-6 knock-out or wild-type islets were isolated and perfused with 
1.7 mM glucose either alone, with 1 µM epinephrine (Epineph 1), or with 20 mM 
arginine (Arg 20). A 5.6 mM glucose wash was performed between secretagogue 
exposures.  
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Epinephrine induced a 2.22 ± 0.09 (p < 0.0001)-fold increase relative to 1.7 mM 
glucose alone (Figure 3.11A). IL-6 alone did not alter [Ca2+]i  (1.89 ± 0.04-fold over 
glucose alone). Surprisingly, co-treatment of islets with IL-6 and epinephrine blunted the 
epinephrine-induced increase in [Ca2+]i (1.5 ± 0.09-fold over 1.7 mM glucose; p = 
0.0008). Therefore, IL-6 is likely exerting its effect on glucagon secretion in a calcium-
independent manner. 
 
Discussion 
 
The results presented herein demonstrate that IL-6 enhances glucagon secretion 
via at least two distinct yet complimentary mechanisms in IL-6 knock-out mice. 
Glucagon is often elevated in inflammatory disease, despite accompanying 
hyperglycemia. Furthermore, inflammatory diseases often associate with autonomic 
Figure 3.11: IL-6 enhances the epinephrine-stimulated glucagon response via a 
calcium-independent mechanism. Islets isolated from GCG-tdRFP mice were 
incubated with the calcium indicator Fluo-4 and placed in a microfluidic device. Islets 
were first incubated with 1.7 mM glucose and subsequently switched to media 
containing 1 µM epinephrine, 200 ng/mL IL-6, or both. Calcium oscillations were 
observed using confocal microscopy. Normalized fluo-4 intensity (Panel A) and 
representative traces (Panel B) are presented. ** = p < 0.005 relative to control and 
*** = p < 0.0005. 
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dysfunction. These studies support a synergistic link between IL-6 signaling and 
autonomic drive to enhance glucagon secretion. The hyperglucagonemia observed in 
certain disease states may result from IL-6-mediated effects on autonomic function. 
Indeed, acute IL-6 delivery 1) enhances neural drive to islets and 2) increases the 
effectiveness of epinephrine at islets to augment glucagon secretion.  
In previous studies, the vascular infusion of IL-6 into IL-6 knock-out mice 
completely restored the glucagon response to LPS (133). We hypothesized that part of 
the rapid glucagon secretory response was via action of IL-6 in the brain. Indeed, 
infusing IL-6 into the lateral ventricle (LV) of IL-6 knock-out mice enhanced LPS-induced 
glucagon secretion by nearly two-fold (a physiologically significant change). Plasma IL-6 
levels were undetectable following these studies, indicating that central IL-6 alone (i.e. 
in the absence of vascular IL-6) was sufficient to augment glucagon secretion in 
response to LPS. Furthermore, we found in a separate cohort of wild-type mice that 
central injection of IL-6 alone did not stimulate glucagon secretion, consistent with our 
data in knock-out mice. These data support our hypothesis that IL-6 mediates the cross 
talk between the brain and pancreas during inflammation. These data are consistent 
with work indicating that IL-6 injected into the LV of the anaesthetized rat (anesthesia is 
a stressor) increases splenic autonomic nerve activity (52). Others have demonstrated 
that pro-inflammatory cytokines in the brain acutely increase sympathetic tone in renal 
failure-induced hypertension (149). Although this work does not directly address the 
regulation of autonomic drive by IL-6, our glucagon secretion data lead us to speculate 
that during settings of stress, IL-6 augments autonomic tone. Unfortunately, 
catecholamine samples were compromised in the LPS experiments. However, based on 
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our previous work, peripheral IL-6 does not augment circulating epinephrine or 
norepinephrine during inflammatory stress (133). Thus, the central effects of IL-6 are 
likely via direct changes in autonomic tone to the pancreas and do not augment adrenal 
catecholamine secretion. Further studies to directly measure autonomic tone to the 
pancreas are needed to corroborate this hypothesis. 
Other groups have found using in vitro or ex vivo models that IL-6 can also 
regulate islet beta cell function (34, 111, 116). While no differences in terminal insulin 
were observed between all cohorts, it is possible that central IL-6 modulated an early 
insulin response to LPS, which was not tested in these studies. An early rise in insulin 
would explain why elevated glucagon would not increase glucose levels following LPS. 
In our hands, we have found that there is a short, transient (~30 min) increase in insulin 
following initial exposure to the selected dose of LPS. Central IL-6 may enhance this 
transient elevation in insulin. However, we would anticipate that glucagon levels would 
actually be reduced in IL-6 treated mice, given that insulin is a negative regulator of 
glucagon secretion. Nonetheless, it is possible that central IL-6 also augmented an early 
insulin response to LPS.  
Our studies point to a dominant role of the sympathetic nervous system in the 
glucagon response to LPS. Sympathetic blockade almost completely blunted the 
glucagon response to LPS in wild-type mice, while parasympathetic blockade did so to 
a lesser degree. Sympathetic blockade also decreased blood glucose levels compared 
to control and to parasympathetic blockade. Hypoglycemia is a potent stimulator of 
glucagon secretion. Despite having both LPS and hypoglycemia on board, sympathetic 
blockade still suppressed glucagon to a greater degree than parasympathetic blockade. 
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While blood glucose levels fell with sympathetic blockade, blood glucose levels 
following LPS treatment were similar in control, parasympathetic, and ganglionic blocker 
treated mice. Propranolol crosses the blood brain barrier, whereas phentolamine, 
atropine, and chlorisondamine do not (98). Thus, propranolol delivery may have 
resulted in off-target effects in the brain. Alternatively, plasma catecholamines may have 
increased and thus kept blood glucose levels from dropping in mice treated with 
parasympathetic blockade (atropine). Unfortunately, the catecholamine samples were 
compromised for these LPS studies, and this remains a point of speculation. These data 
lead us to hypothesize that centrally administered IL-6 may augment sympathetic drive 
to the pancreas in response to LPS.  
We also found that abolishing total neural drive (ganglionic blockade) completely 
blunted the glucagon response to LPS in wild-type mice. In fact, ganglionic blockade 
lowered basal glucagon levels prior to LPS treatment, demonstrating that autonomic 
tone to the pancreas sustains glucagon secretion even in the resting state. Interestingly, 
the plasma IL-6 response to LPS was blunted in mice with ganglionic blockade. This 
contrasts to mice treated with sympathetic or parasympathetic blockade, where plasma 
IL-6 was elevated similar to control-treated mice. Other investigators have found that 
increased adrenergic (sympathetic) and cholinergic (parasympathetic) tone can 
increase local production of IL-6 (19, 89, 101). Since we found that both branches 
contribute to LPS-stimulated glucagon secretion, and both are thus activated in 
response to LPS, the fact that targeting only one branch did not decrease plasma IL-6 
levels is not surprising. These data are consistent with previous work demonstrating that 
vagotomy impaired the pro-inflammatory cytokine mRNA response to LPS in the brain 
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and in the periphery; this was associated with decreased LPS-induced sleep (150). 
Cumulatively, the data lead us to hypothesize that an afferent signal(s) following LPS 
administration leads to elevated pro-inflammatory cytokines in the brain, which, in turn, 
enhances neural drive and amplifies the production of pro-inflammatory cytokines in the 
periphery.  
Hypoglycemia is an alternative setting of both increased plasma IL-6 (30) and 
increased glucagon secretion. Increases in glucagon and autonomic nervous system 
activation work to limit the nadir in blood glucose levels during episodes of 
hypoglycemia. Our studies utilized IL-6 knock-out mice to determine whether central IL-
6 signaling alone was sufficient to enhance glucagon secretion in response to insulin-
induced hypoglycemia. ICV delivery of IL-6 enhanced the rapid rise in glucagon 
secretion. Furthermore, no significant differences in plasma epinephrine were detected 
during hypoglycemia with IL-6 administration. These data imply that IL-6 triggers 
glucagon secretion independent of adrenal function; this is consistent with the 
observation we previously made in the presence of LPS (133). These results are 
consistent with other studies that suggest that separate neural pathways may stimulate 
glucagon and epinephrine secretion in response to glucoprivation (99, 132).  
Since insulin can inhibit glucagon secretion, an alternative inducer of 
hypoglycemia may have yielded more pronounced differences in glucagon secretion 
with central IL-6 administration. In fact, studies replacing insulin with phlorizen (83), an 
SGLT1 and 2 inhibitor that prevents glucose uptake in kidneys, were attempted. There 
were two problems with this technique. First, unlike with insulin, phlorizen does not 
operate over a predictable time-course. The rate of fall in glucose is inconsistent 
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between mice. In order to collect usable data in hypoglycemic clamps, the rate of fall in 
glucose should be similar between mice; this will ensure that the glucagon response 
operates in a similar kinetic manner and thus the glucagon measurements will be more 
consistent between mice. Second, the degree to which glycemia drops is variable and 
sometimes is not enough to yield a significant amount of glucagon secretion. Therefore, 
this technique was not a viable option for the desired purpose. 
Collectively, these in vivo data indicate that central IL-6 augments glucagon 
secretion not only in response to LPS, but also in response to insulin-induced 
hypoglycemia. Further studies are required to delineate the specific site(s) of action and 
mechanism whereby central IL-6 enhances autonomic drive to the pancreas in these 
stressed states.  
IL-6 not only modified neural drive but also acutely modulated glucagon secretion 
in isolated islets in the presence of epinephrine. Ellingsgaard et al. demonstrated that 
human islets incubated with IL-6 undergo a slow-onset increase in glucagon production: 
by 4 hours, there is a significant increase in proglucagon gene expression, and by 24 
hours, there is an increase in secreted glucagon (34). Our islet perifusion experiments 
demonstrated that IL-6 had no acute effect on islets perfused with low glucose alone or 
with arginine, but IL-6 amplified epinephrine-stimulated glucagon secretion. These data 
suggest that the adrenergic signaling pathway may synergize with IL-6 signaling to 
augment glucagon secretion. I have since performed isolated islet culture experiments 
with the Vanderbilt Islet Procurement and Assessment Core with the goal of determining 
through which adrenergic receptor population IL-6 synergizes. However, due to extreme 
inconsistency between experiments, these studies must be redone. A likely explanation 
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of the inconsistency is the manner in which the islets were isolated. Since our 
experience, the Islet Core has found that gradient centrifugation is not an appropriate 
manner to isolate islets when alpha cell function is to be explored, as it damages the 
alpha cells that cover the periphery of mouse islets. Islets must be hand-picked to study 
alpha cell function. Thus, these experiments will need to be repeated.  
The relationship between catecholaminergic and IL-6 signaling in the islet may 
be extrapolated to glucose-sensing regions of the brain. Szepietowska et al. showed 
that modulating adrenergic signaling in the glucose-sensing ventromedial hypothalamus 
(VMH) modulates the glucagon response to insulin-induced hypoglycemia in rats (127). 
Moreover, endogenous production of norepinephrine in this region increases during 
hypoglycemia (11). Since IL-6 receptors are expressed throughout the brain (137), 
adrenergic and IL-6 signaling may synergize not only in the islet, but also in glucose-
sensing regions of the brain.   
Given that calcium can modulate glucagon secretion, we determined whether IL-
6 could enhance epinephrine-stimulated calcium signaling. Surprisingly, IL-6 actually 
reduced the epinephrine-stimulated increase in calcium oscillations while not altering 
basal calcium oscillations. These data suggest that epinephrine and IL-6 synergize to 
increase glucagon secretion through a calcium-independent mechanism. Both IL-6 and 
catecholaminergic signaling (Gq-coupled) may converge at the level of the MAPK/ERK 
signaling pathway. Moreover, ERK has been implicated as a positive effector of 
glucagon secretion (21). IL-6 and catecholaminergic signals may operate through the 
ERK signaling pathway to increase glucagon production. Further studies are needed to 
address this possibility. 
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Both our in vivo and ex vivo data suggest that IL-6 does not by itself acutely 
modulate glucagon secretion. It is only in the presence of an additional stressor that IL-6 
augments glucagon secretion. Both LPS and hypoglycemia are associated with 
increased autonomic tone. Our islet perifusion data used epinephrine as a surrogate for 
elevated adrenergic tone at the islet. It was only with epinephrine that we saw the ability 
of IL-6 to amplify glucagon secretion. What occurs during this shift in autonomic tone 
that allows for IL-6 to presumably amplify neural drive to the pancreas and increase 
glucagon secretion is yet to be elucidated.  
A great body of work in a critical glucose-sensing region of the brain, the 
ventromedial hypothalamus (VMH) (130), points to a potential mechanism by which 
central IL-6 may enhance glucagon secretion in settings of stress. Local induction of 
glucopenia in this region results in increased systemic levels of glucagon and 
epinephrine (EPI) (14), and delivery of glucose in the VMH during systemic glucopenia 
prevents the release of these hormones (12). Increasing adrenergic signaling in the 
VMH increases the glucagon response to hypoglycemia, while blocking adrenergic 
signaling decreases the response (127). Furthermore, norepinephrine levels increase in 
the VMH during hypoglycemia (11), and norepinephrine can increase local production of 
IL-6 (81, 96). These data, when combined with our findings that catecholaminergic 
signaling and IL-6 signaling pathways synergize in islets, lead us to speculate that a 
similar synergy may also happen within the VMH and potentially other glucoregulatory 
brain regions. IL-6 receptors are abundant throughout the hypothalamus, including 
within the VMH (137). In a separate cohort of mice, we also found that administration of 
IL-6 to the lateral ventricle activates phosphorylation of STAT3 (an index of IL-6 
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signaling) in regions surrounding the ventricles, including the VMH (Figure 3.12). 
Furthermore, pathophysiologic settings such as endotoxemia or physiologic settings 
such as hypoglycemia are also associated with elevated adrenergic tone and elevated 
IL-6. Therefore, it is possible that IL-6 signaling in the brain may synergize with 
catecholaminergic signaling to amplify the glucagon response in each of these settings. 
 
 
 
Figure 3.12: IL-6 increases phosphorylation of STAT-3 in regions surrounding 
cerebral ventricles. Wild-type mice were cannulated in the lateral ventricle as 
described for IL-6 knock-out mice in the materials and methods section of this 
dissertation. Mice were subsequently injected with 200 ng of IL-6   (in   a   2   μl  
microbolus) or vehicle control, and 30 min later, mice were sacrificed. Brains were 
fixed, cryoprotected, and immunohistochemically assessed for an index of IL-6 
signaling (phospho-STAT3, tyrosine 705). Regions surrounding the ventricles such 
as the paraventricular nucleus of the hypothalamus (PVN), dorsomedial 
hypothalamus (DMH), ventromedial hypothalamus (VMH), and arcuate nucleus of the 
hypothalamus (ARC) were positive for p-STAT3 following central IL-6 injection.  
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Clinical research has demonstrated that targeting the IL-6 pathway is of benefit to 
diabetic patients. Tocilizumab is a humanized IL-6   receptor   (IL6Rα)   antibody   used  
clinically to treat rheumatoid arthritis (RA). When administered to diabetics with RA, 
tocilizumab reduced HbA1C in type 2 diabetics compared to those without diabetes, 
who showed no changes in HbA1C (97). While the concurrent RA of these patients 
complicates this particular study, targeting the IL-6 pathway clearly shows promise in 
lowering HbA1C levels. We speculate that tocilizumab may suppress glucagon 
secretion and thus contribute to the improvement of HbA1C levels in these patients. 
Reducing glucagon production via IL-6 antagonism may represent an additional 
treatment option in diabetics with hyperglucagonemia. As chronic levels of circulating IL-
6 can also contribute to reduced insulin sensitivity in adipose, muscle, and liver (18, 65, 
66, 68, 95, 108), reducing IL-6 signaling could have benefits beyond controlling 
glucagon levels.   
 In summary, our data support IL-6 as an important driver of glucagon secretion. 
IL-6 exerts its actions via at least two mechanisms: IL-6 (1) acts centrally to enhance 
glucagon secretion in response to both inflammation and insulin-induced hypoglycemia, 
and (2) enhances epinephrine-stimulated glucagon secretion in the islet. Thus, IL-6 may 
modulate glucagon secretion in vivo by augmenting neural drive to the pancreas and 
amplifying the effects of circulating epinephrine or neural drive directly at the pancreas. 
However, future work is needed to demonstrate that both effects are happening 
simultaneously in vivo as well as to determine whether varying concentrations of IL-6 
will yield similar results. IL-6 is elevated in multiple disease states, many of which 
associate with autonomic dysfunction. These findings implicate IL-6 in contributing to 
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the hyperglucagonemia that exists in multiple inflammatory settings. The IL-6 signaling 
pathway may represent a novel target in the treatment of glucoregulatory disorders that 
are also characterized by autonomic dysfunction.  
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CHAPTER IV: CONCLUSIONS 
 
Collectively, the results presented within this dissertation point to a modulatory 
role of IL-6 on glucagon secretion that, contrary to the original hypothesis, is not only via 
its action within the brain, but also via its action within islets. Thus, IL-6 enhances 
glucagon secretion by at least two distinct yet complimentary mechanisms.  
First, IL-6 is able to augment glucagon secretion via the brain. Central IL-6 
administration alone has no acute effect on glucagon secretion in either IL-6 knock-out 
or wild-type mice. However, administration of the cytokine centrally enhances the 
glucagon response in IL-6 knock-out mice to two different settings associated with 
elevated autonomic drive: endotoxemia (LPS) and hypoglycemia. While these settings 
of enhanced glucagon secretion seem at first entirely different, they are both associated 
with elevated pro-inflammatory cytokines and autonomic drive. However, the body of 
work in this dissertation did not determine whether autonomic drive to the pancreas is 
similarly modulated by both stimuli. This is one potential future direction for this project 
(see Chapter V).  
Second, IL-6 can act directly on islets in the presence of elevated adrenergic 
tone (epinephrine). Previous work has demonstrated that IL-6 has a slow, transcriptional 
effect on glucagon production (34). The studies within this body of work demonstrate 
that IL-6 does not acutely (i.e. within minutes) modulate glucagon secretion. However, 
IL-6 does acutely modulate glucagon secretion in the presence of epinephrine. Given 
that epinephrine is elevated following LPS exposure and during insulin-induced 
hypoglycemia, this work suggests that IL-6 can not only modulate autonomic drive to 
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the islet, but it can also modulate the effects of autonomic drive (i.e. epinephrine) on the 
islets (Figure 4.1). 
 
 
 
 
 
While historic literature supports the involvement of the autonomic nervous 
system (ANS) in the glucagon response to hypoglycemia (50, 51, 128), the role of the 
ANS in the glucagon response to LPS has not been characterized. The findings of this 
dissertation suggest that in wild-type mice, both the sympathetic and parasympathetic 
nervous systems are involved in the glucagon secretory response to LPS. When both 
branches of the ANS are inhibited via ganglionic blockade, glucagon secretion following 
LPS is maximally suppressed. Interestingly, so is plasma IL-6. These data suggest that 
the ANS is highly involved in the peripheral inflammatory response to LPS.   
Figure 4.1: IL-6 stimulates glucagon secretion by direct 
actions on the pancreas and by actions within the brain.  
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CHAPTER V: FUTURE DIRECTIONS 
 
The work presented within this dissertation has further characterized the manner 
by which IL-6 effects glucagon secretion. Not only can IL-6 function within the brain in 
settings of stress to augment glucagon secretion, but the cytokine can also enhance 
glucagon secretion by direct action on islets in settings of stress simulated by elevated 
epinephrine. While the findings of this dissertation offer insights into the nature of IL-6 in 
the setting of a stressor, several important questions remain.  
 
 
Where does IL-6 signal in the brain to enhance glucagon secretion in settings of 
stress? 
 
Perhaps one of the first questions to be answered is where IL-6 functions in the 
brain to enhance the glucagon response during both hypoglycemia and acute 
inflammation (LPS). Beyond the sites of IL-6 action, is it possible that the neural drivers 
culminating in glucagon and epinephrine secretion in these settings are shared? To 
expand, when blood glucose drops (such as after a long fast or following insulin 
injection), our body has a normal response to limit the nadir in blood glucose, thus 
ensuring that the brain has an adequate supply of glucose. This normal physiologic 
response to hypoglycemia involves increased pro-inflammatory cytokine production (30) 
as well as activation of specific neural circuits that enhance autonomic drive to the 
pancreas and adrenal gland (8). Given that inflammation is another setting associated 
with enhanced autonomic drive coupled to an increase in pro-inflammatory cytokines, it 
is reasonable to assume that the body may utilize this existing system during 
inflammatory events.  
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Using c-fos as a marker for neural activation, we can speculate that there are 
regions that are similarly activated during both hypoglycemia and acute inflammation. 
Multiple groups demonstrated that intraperitoneal injection of LPS results in robust 
activation of c-fos in the paraventricular nucleus of the hypothalamus (PVH) as well as 
in the nucleus tractus solitarius (an area from which neural projections extend to the 
PVH) 3 hours following injection (138, 142). Further, Diggs-Andrews found elevated c-
fos in the PVH of mice 2 hours following a bolus of insulin to achieve hypoglycemia (29). 
The PVH is an area that receives many inputs from glucose-sensing brain regions (8) 
as well as an area from which pre-motor neurons controlling peripheral outputs project 
to the pancreas, as evidenced by pseudorabies virus retrograde tracking (75). See 
Figure 1.3 for a schematic of glucose-sensing circuitry.  
Although these studies did not define the type of projection neurons from which 
these pre-motor neurons extend, others have found sympathetic fibers (fibers staining 
positive for tyrosine hydroxylase, the enzyme precursor to dopamine and 
norepinephrine) extending and making connections to alpha cells of mouse islets (20). 
Parasympathetic fibers (fibers staining positive for the vesicular acetylcholine 
transporter) were also found to extend throughout mouse islets (107). Although 
expression of the IL-6 receptor (IL-6Rα) mRNA is not detectable at rest in the PVH 
(112), IL-6R mRNA is increased in the PVH 3 hours following LPS injection (138). The 
PVH, therefore, may represent a site by which IL-6 may augment glucagon secretion in 
settings of stress.  
While the PVN has been demonstrated to be a critical integration site for glucose 
homeostasis (8), the site many investigators consider to be most critical for glucose 
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sensing itself is the ventromedial hypothalamus (VMH). The VMH is one of many central 
glucose-sensing regions that projects to the PVN. The VMH is thought to indirectly elicit 
pancreatic responses from peripheral motor neurons based on pseudorabies tracking 
studies (75). Nonetheless, this particular region has become defined as critical for the 
glucagon and epinephrine responses to hypoglycemia. Whether this same circuitry is 
harnessed for the glucagon or epinephrine response to inflammatory stress remains to 
be determined. Unlike in the PVH, the VMH also expresses the IL-6 receptor (IL-6Rα) in 
the unstimulated state. However, Vallieres and colleagues did not observe a further 
increase in VMH IL-6R mRNA expression following LPS exposure (112). Moreover, they 
also did not observe an increase in VMH c-fos following LPS exposure, although more 
recently, others have produced data that conflicts with this finding (43). In sum, the VMH 
stands out as another potential site where IL-6 may augment glucagon secretion in 
settings of stress. In fact, it is possible that IL-6 may act via both nuclei to elicit its effect 
on glucagon. 
 The work presented within this dissertation demonstrates that IL-6 injection into 
the lateral ventricle is sufficient to enhance glucagon secretion not only in response to 
LPS, but also in response to insulin-induced hypoglycemia. Both endotoxemia (LPS) 
and hypoglycemia are two settings of enhanced autonomic drive. Moreover, both of 
these drivers of glucagon secretion are also associated with acute neuroinflammation. 
Therefore, it is conceivable that the same circuitry that is harnessed to facilitate the 
glucagon response to hypoglycemia may be the very same circuitry that is utilized in the 
response to LPS. Whether the response occurs in well-characterized glucoregulatory 
nuclei such as the PVH or VMH remains to be defined. Future studies comparing c-fos 
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activation in the brain between mice lacking IL-6 and wild-type mice during both 
hypoglycemia and acute inflammation may allow for initial parsing apart of what regions 
are affected by IL-6. An additional IL-6 knock-out + central IL-6 injection (rescue) would 
be an important control in this case. These studies would also help define any 
differences between acute inflammation and hypoglycemia in terms of activated (c-fos) 
nuclei.  
 
What is the contribution of peripheral IL-6 signaling versus central IL-6 signaling 
in the glucagon response to stressors?  
 
The studies performed for this dissertation suggest that the CNS plays a critical 
role in the glucagon response to inflammation. Previous data has also confirmed the 
crucial involvement of the brain in the counter-regulatory response to hypoglycemia. 
However, the work contained herein as well as previous work did not measure the 
relative contribution of central versus peripheral IL-6 signaling simultaneously during a 
stress in vivo. Wild-type mice were used in the pharmacologic studies to determine the 
role of the autonomic nervous system (ANS) in the glucagon response to inflammation. 
While IL-6 levels normally surge following LPS injection (and did in control mice), IL-6 
levels were greatly blunted following ganglionic blockade. These data make it difficult to 
untangle whether the resultant loss in the glucagon secretory response following LPS 
administration was due to a loss of IL-6’s  ability   to  modulate  central  drive  or  a   loss  of  
plasma IL-6 interacting with epinephrine or norepinephrine that might normally occur 
due to the enhanced autonomic drive. The other pharmacologic studies targeting 
specific branches of the ANS do not provide enough information to determine the 
relative importance of central versus peripheral IL-6 signaling, either. Additional in vivo 
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studies need to be performed to elucidate the relative importance of IL-6 action directly 
on the pancreas versus IL-6 action within the brain.  
A study performed by Zielinski and colleagues demonstrates the importance of 
vagal afferents in the response to LPS (in this case, the readout for a response to LPS 
was sleep). Mice administered an intraperitoneal bolus of LPS experience decreased 
sleep when they are vagotomized (150). Importantly, vagotomy not only reduced central 
neuroinflammation in response to LPS, but it also reduced plasma pro-inflammatory 
cytokines. This study suggests that 1) vagal afferents are critical for a full inflammatory 
response to LPS, and 2) vagal afferents contribute to the increased central production 
of pro-inflammatory cytokines in settings of stress. The liver is innervated by vagal 
afferents, which respond to inflammatory cytokines (26), including IL-6, which triggers 
production of hepatic acute phase proteins. Hepatic vagal afferents project to the 
nucleus tractus solitarius (NTS), which, as previously mentioned, sends projections to 
the PVH, an area that is activated (as indicated by c-Fos) following LPS administration 
(138, 142) and also itself upregulates expression of IL-6R during acute inflammation 
(138). These data lead to the question of whether peripheral IL-6 signaling in the liver 
indirectly contributes to the secretion of glucagon in settings of inflammation. Moreover, 
plasma IL-6 is elevated during hypoglycemia in healthy individuals (30) as well as in the 
resting state in obese individuals (33). Whether vagal IL-6 signaling via the liver 
contributes to glucagon secretion in these settings is an interesting question that should 
be further explored (Figure 5.1). Studies utilizing vagotomized mice in the presence or 
absence of IL-6 (wild-type vs. knock-out) would be an informative starting point. A 
stronger future direction of these studies might use either hepatocyte-specific IL-6 
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receptor (IL-6Rα) knock-out (84) or an adenoviral dominant negative IL-6 receptor (IL-
6Rα) via tail vein injection in the presence or absence of vagotomy compared to 
controls. The advantage of an adenoviral injection approach is that hepatocytes as well 
as other hepatic cellular populations such as Kupffer cells (145), the immune cells that 
found interspersed among vagal fibers and also express the IL-6 receptor (26), will be 
targeted.  
 
 
 
 
 
Previously in this dissertation, a study was discussed wherein Tocilizumab, a 
humanized IL-6 receptor antibody, was administered to diabetic patients with 
rheumatoid arthritis, and HbA1c improved upon treatment (97). Although it is common 
Figure 5.1: IL-6 stimulates glucagon secretion by direct actions 
on the pancreas and by actions within the brain. Does it also 
work via vagal input to the brain?  
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that individuals with type 1 diabetes have elevated plasma glucagon or at least an 
elevation in the ratio of glucagon to insulin, glucagon was not assessed in these studies. 
One possible way by which Tocilizumab may have reduced blood glucose is by 
reducing plasma glucagon. By inhibiting the ability of IL-6 to signal peripherally (not 
centrally, as the antibody would not cross the blood-brain barrier), vagal afferent input 
may have been reduced. By reducing vagal afferent input, neuroinflammation may also 
have been reduced, and this, in turn, may have reduced autonomic drive to the 
pancreas, thereby reducing glucagon production. The concept of targeting IL-6 
peripherally rather than centrally makes the IL-6 pathway an exciting and viable 
therapeutic option. 
 
How does IL-6 signaling synergize with epinephrine signaling?  
 
The data generated in islets suggests that IL-6 augments glucagon secretion in 
the presence of epinephrine (which is elevated in settings of stress) in a calcium-
independent manner. Epinephrine is a nonselective agonist for adrenergic receptors 
and therefore could bind to either of the adrenergic receptors expressed on alpha cells. 
Islet alpha cells express primarily α1   (Gαq-coupled)   and   β2   (Gαs-coupled) adrenergic 
receptors. As the synergy of IL-6 and epinephrine is calcium-independent, one would 
speculate that the synergy is likely not via Gαq-coupled (α1) signaling. However, another 
result of Gαq-coupled signaling is activation of protein kinase C (PKC) (Figure 5.2). In 
some cell populations, activation of PKC activates the MAPK/ERK pathway (134). As 
described in the introduction, the IL-6 signaling pathway also shares the MAPK/ERK 
pathway. Moreover, ERK has been implicated as a positive effector of glucagon 
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secretion (21).  Therefore,  synergy  between  these  pathways  via  α1  adrenergic  signaling  
is an interesting possibility that should be further explored.  
Given that calcium signaling was not enhanced by epinephrine in the presence of 
IL-6, synergy between IL-6  signaling  and  β2  adrenergic  signaling  may  be  a  more  viable  
explanation. Further,  pharmacologic  studies  have  suggested  that  β  adrenergic  signaling  
may predominate in epinephrine-stimulated glucagon secretion (140). The   β2  
adrenergic   receptor  operates  via  a  Gαs-coupled mechanism, which results in elevated 
levels of cyclic adenosine monophosphate (cAMP). There are data to suggest that 
cAMP may also be involved in glucagon secretion (131), and experiments using 
forskolin (which increases cellular cAMP) or IBMX (a phosphodiesterase inhibitor which 
indirectly raises cAMP) point to the role of cAMP in epinephrine-stimulated glucagon 
secretion (31, 123). How may the IL-6 signaling pathway converge with the   β2  
adrenergic signaling pathway? One of the messengers activated by IL-6 signaling 
through its receptor is ERK. Although not yet demonstrated in islet alpha cells, ERK has 
been found in other cell populations to inhibit phosphodiesterase activity (118). Given 
that others have found inhibition of phosphodiesterase to result in alpha cell glucagon 
secretion (123), it is possible that IL-6 augments epinephrine-stimulated glucagon 
secretion by decreasing the activity of phosphodiesterase, thereby amplifying 
intracellular cAMP and stimulating glucagon secretion.  
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Beyond understanding the signaling cascade that results in enhanced glucagon 
secretion under settings of stress, another question which remains is whether the 
synergy that happens between adrenergic and IL-6 signaling in the islet alpha cell may 
also happen in other electrically excitable cell populations—neurons. The similarities 
and differences between these signaling events represent an exciting new path of 
discovery. 
Figure 5.2: The proposed mechanism for IL-6 to enhance epinephrine-
stimulated glucagon secretion. There are currently two hypotheses that may 
occur simultaneously. First, via ERK, IL-6 reduces phosphodiesterase activity, 
thereby  enhancing  the  pool  of  cAMP  during  β-adrenergic stimulation and increasing 
glucagon secretion. Alternatively (or concurrently), IL-6 reduces activity of 
phosphodiesterase,  and  α-adrenergic input further reduces the pool by increasing 
ERK phosphorylation via PKC.     
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What role might other cytokines have in the IL-6-mediated enhancement of 
glucagon secretion? 
 
 Based on the initial studies demonstrating that IL-6 completely rescues the 
glucagon response to LPS while not altering concentrations of other plasma pro-
inflammatory cytokines such as IL-1 beta or TNF-alpha, this led to a focus solely on IL-6 
as the driver for glucagon secretion. However, it should be emphasized that during an 
inflammatory event, IL-6 does not exist alone. IL-6 is present amid a variety of 
hormones and other cytokines (both inflammatory and anti-inflammatory).  
For example, others have claimed that IL-1β and IL-6 signaling pathways may 
synergize in the brain (117). In light of work suggesting IL-1 beta can signal through 
ERK in other cell populations (29), synergy between IL-1 beta and IL-6 would be 
consistent with the hypothesis that ERK signaling is responsible for augmenting 
catecholaminergic-stimulated glucagon secretion (see Future Direction 3 above). 
Alternatively, given that the earlier study observing synergy between the two pathways 
observed synergy during a longer-term study (food intake), IL-1 beta-mediated 
production of NF- kappa B could have also increased expression of IL-6. The first 
logical step for this project would be to assess the effect of IL-6 in the presence or 
absence of IL-1β   ex vivo on islet catecholaminergic signaling. This would involve a 
series of perifusion experiments that compare the glucagon response of islets to 
epinephrine in the presence or absence of IL-1 beta. These studies would then be 
compared to studies where both IL-6 and IL-1 beta are administered to islets. If IL-6 and 
IL-1 beta are synergistic, the glucagon response to epinephrine will be further 
augmented above the degree to which IL-6 augments the response. The amount of 
treatment groups in this proposed experiment is large, however. A more straightforward 
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static incubation approach may be simpler, although kinetic data that could be gleaned 
from these experiments (i.e. how rapid the glucagon secretory response is) would be 
limited. To conclude, to fully understand the effects of IL-6, more work must be done to 
examine the actions of IL-6 in light of other cytokines or hormones that may also 
influence its action.   
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